acid form of hepcidin is a simple hairpin with 8 cysteines that form 4 disulfide bonds as described by Jordan et al. J Biol Chem 284:24155-67. The N terminal region is required for iron-regulatory function, and deletion of 5 N-terminal amino acid residues results in a loss of iron-regulatory function. See Nemeth et al. (2006) Blood 107:328-33.

**[0005]** Abnormal hepcidin activity is associated with iron overload diseases, including hereditary hemochromatosis (HH) and iron-loading anemias. Hereditary hemochromatosis is a genetic iron overload disease that is mainly caused by hepcidin deficiency or in some cases by hepcidin resistance. This allows excessive absorption of iron from the diet and development of iron overload. Clinical manifestations of HH may include liver disease (e.g., hepatic cirrhosis NASH, and hepatocellular carcinoma), diabetes, and heart failure. Currently, the only treatment for HH is regular phlebotomy, which is very burdensome for the patients. Iron-loading anemias are hereditary anemias with ineffective erythropoiesis such as β-thalassemia, which are accompanied by severe iron overload. Complications from iron overload are the main causes of morbidity and mortality for these patients. Hepcidin deficiency is the main cause of iron overload in non-transfused patients, and contributes to iron overload in transfused patients. The current treatment for iron overload in these patients is iron chelation, which is very burdensome, sometimes ineffective, and accompanied by frequent side effects.

**[0006]** Hepcidin has several limitations that restrict its use as a drug, including a difficult synthetic process due in part to aggregation and precipitation of the protein during folding, which in turn leads to low bioavailability, injection site reactions, immunogenicity, and high cost of goods. What are needed in the art are compounds having hepcidin activity and also possessing other beneficial physical properties such as improved solubility, stability, and/or potency, so that hepcidin-like compounds might be produced affordably and used to treat hepcidin-related diseases and disorders such as, e.g., those described herein.

**[0007]** The present invention addresses such needs, providing novel peptide analogues, including both peptide monomer analogues and peptide dimer analogues, having hepcidin activity, and also having other beneficial properties making the peptides of the present invention suitable alternatives to hepcidin.

## BRIEF SUMMARY

**[0008]** The present disclosure generally relates to peptide analogues, including both monomer and dimers, exhibiting hepcidin activity and methods of using the same.

**[0008a]** In one aspect, the present disclosure provides a hepcidin analogue comprising a peptide according to Formula I': $R^1$-Xbb1-Thr-X3-B1-B2-B3-B4-Xaa1-B6-Xaa2-J-Y1-Y2-$R^2$ (I') or a pharmaceutically acceptable salt or solvate thereof, wherein: $R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, $C_2$-$C_{20}$ alkenoyl, or $C_1$-$C_{20}$ cycloalkanoyl; $R^2$ is $NH_2$ or OH; Xbb1 is Asp, isoAsp, Asp(OMe), Gly, substituted Gly, Glu, substituted Glu, isoGlu, (D)Glu, (D)isoGlu, bhGlu, bGlu, Gla, or Glp; X3 is His or substituted His; each Xaa1 and Xaa2 is independently Ala, Gly, N-substituted Gly, Lys, (D)Lys, Lys(Ac), or (D)Lys(Ac); or Xaa1 is B5; and B5 is absent, Lys, D-Lys, (D)Leu, (D)Ala, a-Me-Lys, or Lys(Ac); and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys; or Xaa1 is B5(L1Z); B5 is Lys, D-Lys, or Lys(Ac); and Xaa2 is B7; and B7 is Glu or absent; each of B1 and B6 is independently Gly, substituted Gly, Phe, substituted Phe, Dpa, substituted Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal; B2 is Pro, substituted Pro, propanoicPro, butanoicPro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC; B3 is Cys, homoCys, (D)Cys, a-MeCys, or Pen; B4 is Gly, N-substituted Gly, Ile, (Me)Ile, Val, Leu, or NLeu; L1 is absent, Dapa, D-Dapa, or isoGlu, PEG, Ahx, isoGlu-PEG, isoGlu-PEG, PEG-Ahx, isoGlu-Ahx, or isoGlu-PEG-Ahx; wherein Ahx is an aminohexanoic acid moiety; PEG is $-[C(O)-CH_2-(Peg)_n-N(H)]_m-$, or $-[C(O)-CH_2-CH_2-(Peg)_n-N(H)]_m-$; and Peg is $-OCH_2CH_2-$, m is 1, 2, or 3; and n is an integer between 1-100K; Z is a half-life extension moiety; J is absent, any amino acid, or a peptide chain consisting of 1-5 amino acids, wherein each amino acid is independently selected from Pro, (D)Pro, hydroxyPro, hydroxy(D)Pro, Arg, MeArg, Lys, (D)Lys, Lys(Ac), (D)Lys(Ac), Ser, MeSer, Sar, and Gly; Y1 is Abu, Cys, homoCys, (D)Cys, NMeCys, aMeCys, or Pen; Y2 is an amino acid or absent; Dapa is diaminopropanoic acid, Dpa or DIP is 3,3-diphenylalanine or b,b-diphenylalanine, bhPhe is b-homophenylalanine, Bip is biphenylalanine, bhPro is b-homoproline, Tic is L-1,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid, NPC is L-nipecotic acid, bhTrp is b-homoTryptophane, 1-Nal is 1-naphthylalanine, 2-Nal is 2-naphthylalanine, Orn is orinithine, Nleu is norleucine, Abu is 2-aminobutyric acid, 2Pal is 2-pyridylalanine, Pen is penicillamine; substituted Phe is phenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine; substituted bhPhe is b-homophenylalanine wherein phenyl is substituted with


F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine; substituted Trp is N-methyl-L-tryptophan, a-methyltryptophan, or tryptophan substituted with F, Cl, OH, or t-Bu; and substituted bhTrp is N-methyl-L-b-homotryptophan, a-methyl-b-homotryptophan, or b-homotryptophan substituted with F, Cl, OH, or t-Bu; wherein i) the peptide of formula I is optionally PEGylated on one or more of $R^1$, B1, B2, B3, B4, B5, B6, B7, J, Y1, Y2, or R2; and ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1; provided that when Xbb1 is Asp, then $R^1$ is $C_2$-$C_{20}$ alkenoyl.

**[0008b]** In another aspect, the present disclosure provides a A hepcidin analogue comprising a peptide according to claim 1, further according to Formula I: $R^1$-Xbb1-Thr-His-B1-B2-B3-B4-Xaa1-B6-Xaa2-J-Y1-Y2-$R^2$ (I) or a pharmaceutically acceptable salt or solvate thereof, wherein: $R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, or $C_1$-$C_{20}$ cycloalkanoyl; $R^2$ is $NH_2$ or OH; Xbb1 is isoAsp, Asp(OMe), Gly, substituted Gly, Glu, substituted Glu, bhGlu, bGlu, Gla, or Glp; each Xaa1 and Xaa2 is independently Gly, N-substituted Gly, Lys, (D)Lys, Lys(Ac), or (D)Lys(Ac); or Xaa1 is B5; and B5 is absent, Lys, D-Lys, (D)Leu, (D)Ala, or Lys(Ac); and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys; or Xaa1 is B5(L1Z); B5 is Lys, D-Lys, or Lys(Ac); and Xaa2 is B7; and B7 is Glu or absent; each of B1 and B6 is independently Gly, substituted Gly, Phe, substituted Phe, Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal; B2 is Pro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC; B3 is Cys, homoCys, (D)Cys, a-MeCys, or Pen; B4 is Gly, N-substituted Gly, Ile, (Me)Ile, Val, Leu, or NLeu; L1 is absent, Dapa, D-Dapa, or isoGlu, PEG, Ahx, isoGlu-PEG, isoGlu-PEG, PEG-Ahx, isoGlu-Ahx, or isoGlu-PEG-Ahx; wherein Ahx is an aminohexanoic acid moiety; PEG is –[C(O)-$CH_2$-$(Peg)_n$-N(H)]$_m$-, or –[C(O)-$CH_2$-$CH_2$-$(Peg)_n$-N(H)]$_m$-; and Peg is -$OCH_2CH_2$-, m is 1, 2, or 3; and n is an integer between 1-100K; Z is a half-life extension moiety; J is Lys, D-Lys, Arg, Pro, -Pro-Arg-, -Pro-Lys-, -Pro-(D)Lys-, -Pro-Arg-Ser-, -Pro-Arg-Ser-Lys-(SEQ ID NO:249), -Pro-Arg-Ser-Lys-Sar-(SEQ ID NO:250), -Pro-Arg-Ser-Lys-Gly- (SEQ ID NO:251), -His-(D)Phe-Arg-Trp-Cys-, or absent; or J is any amino acid; Y1 is Cys, homoCys, (D)Cys, NMeCys, aMeCys, or Pen; Y2 is an amino acid or absent; Dapa is diaminopropanoic acid, Dpa or DIP is 3,3-diphenylalanine or b,b-diphenylalanine, bhPhe is b-homophenylalanine, Bip is biphenylalanine, bhPro is b-homoproline, Tic is L-1,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid, NPC is L-nipecotic acid, bhTrp is b-


homoTryptophane, 1-Nal is 1-naphthylalanine, 2-Nal is 2-naphthylalanine, Orn is orinithine, Nleu is norleucine, Abu is 2-aminobutyric acid, 2Pal is 2-pyridylalanine, Pen is penicillamine; substituted Phe is phenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine; substituted bhPhe is b-homophenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine; substituted Trp is N-methyl-L-tryptophan, a-methyltryptophan, or tryptophan substituted with F, Cl, OH, or t-Bu; and substituted bhTrp is N-methyl-L-b-homotryptophan, a-methyl-b-homotryptophan, or b-homotryptophan substituted with F, Cl, OH, or t-Bu; wherein i) the peptide of formula I is optionally PEGylated on one or more of $R^1$, B1, B2, B3, B4, B5, B6, B7, J, Y1, Y2, or R2; and ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1.

**[0008c]** In another aspect, the present disclosure provides a hepcidin analogue, or a pharmaceutically acceptable salt or solvate thereof, comprising or consisting of a peptide according to claim 1, wherein the peptide is:


Compound ID# 12




Compound ID# 19




Compound ID# 107




Compound ID# 113




Compound ID# 256




Compound ID# 257




Compound ID# 280



Compound ID# 281




Compound ID# 255



or

Compound ID 280



.

**[0008d]** In another aspect, the present disclosure provides a hepcidin analogue, or a pharmaceutically acceptable salt or solvate thereof, comprising or consisting of a peptide according to claim 1, wherein the peptide is any one of the following:

| **Compound # / SEQ ID No.** | **Peptide** |
|---|---|
| Ref. Compd. 2 (Ref-1) | Isovaleric acid-DTHFPCIKF-Lys[2Peg11'-Palm]-PRSKGCK-$NH_2$ |
| 1 | Isovaleric Acid-E-T-H-F-P-[Cys]-I-[(D)Lys]-F-[Lys(2Peg11'_Palm)]-K-[Cys]-$NH_2$; |
| 2 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[Dpa]-[Lys(2Peg11'_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 3 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 4 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Palm)]-[Cys]-[(D)Lys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 5 | Isovaleric Acid-E-T-H-[Dpa]-[Npc]-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 6 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 7 | Isovaleric Acid-[bhGlu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 8 | Isovaleric Acid-[bGlu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 9 | Isovaleric Acid-[(OMe)Asp]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 10 | Isovaleric Acid-[Gla]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 11 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-R-[Cys]-$NH_2$; |
| 12 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 13 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 14 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 15 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-R-[Cys]-$NH_2$; |
| 16 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-R-[Cys]-$NH_2$; |
| 17 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Palm)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 18 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys(2Peg11'_OMe)]-[bhPhe]-[Lys(Ahx_Palm)]-R-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 19 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys(2Peg11'_OMe)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys(2Peg11'_OMe)]-[Cys]-$NH_2$; |
| 20 | Isovaleric Acid-[Glp]-T-H-F-P-[Cys]-I-Z_minus-F-E-P-R-S-K-G-[Cys]-K-$NH_2$; |
| 21 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Palm)]-[2Pal]-[Cys]-$NH_2$; |
| 22 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Palm)]-[2Pal]-R-[Cys]-$NH_2$; |
| 23 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-[2Pal]-R-[Cys]-$NH_2$; |
| 24 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-[2Pal]-R-[Cys]-$NH_2$; |
| 25 | Isovaleric Acid-E-T-H-F-P-[Cys]-I-K-F-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-P-R-S-K-[Sarc]-[Cys]-K-$NH_2$; |
| 26 | Isovaleric Acid-E-T-H-F-P-[Cys]-I-K-F-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-P-R-S-K-[Sarc]-[Cys]-K-$NH_2$; |
| 27 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 28 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[a-MePhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 29 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 30 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Ahx_IsoGlu_C18Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 31 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Ahx_IsoGlu_Behenic_acid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 32 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 33 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 34 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 35 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ado_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 36 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ado_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 37 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ado_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 38 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_2Peg11'_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 39 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg4_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 40 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg4_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 41 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 42 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-K-R-[Cys]-$NH_2$; |
| 43 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-K-R-[Cys]-$NH_2$; |
| 44 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx)]-R-[Cys]-$NH_2$; |
| 45 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-K-[bhPhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 46 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[Lys(2Peg20K)]-R-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 47 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-[Lys(2Peg20K)]-R-[Cys]-$NH_2$; |
| 48 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx_PEG20K)]-R-[Cys]-$NH_2$; |
| 49 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg20K)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 50 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg20K)]-[bhPhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 51 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_PEG20K)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 52 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys([Lys(2_2Peg11'_Palm)])]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 53 | Isovaleric Acid-E-T-H-[(4F)Phe]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 54 | Isovaleric Acid-E-T-H-[(4CF3)Phe]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 55 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[(4F)Phe]-[(D)Lys]-[Cys]-$NH_2$; |
| 56 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[(4CF3)Phe]-[(D)Lys]-[Cys]-$NH_2$; |
| 57 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_KKK_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 58 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_DEKHKS_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 59 | Isovaleric Acid-E-T-H-[(2,3,5-trifluoro)Phe]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 60 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1Peg2_Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 61 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg8_Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 62 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 63 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg8_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 64 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 65 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_[Lys(DEKHKS_Palm)])]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 66 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_KKKG_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 67 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[a-MePhe]-[Lys(2Peg11'_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 68 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(IsoGlu_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 69 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg4_Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 70 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 71 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Lys[2Peg11'_Palm]2)]-[(D)Lys]-[Cys]-$NH_2$; |
| 72 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_AlbuTag)]-[(D)Lys]-[Cys]-$NH_2$; |
| 73 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_C18_Diacid)]-[(D)Lys]-[Cys]-$NH_2$; |
| 74 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Palm)]-[(D)Lys]-[Pen]-$NH_2$; |
| 75 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Ala]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 76 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Ala]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 77 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Pen]-$NH_2$; |
| 78 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 79 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[Cys]-$NH_2$; |
| 80 | Isovaleric Acid-E-T-H-[(Me)Phe]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 81 | Isovaleric Acid-E-T-H-[Dpa]-P-[(Me)Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 82 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-[(Me)Ile]-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 83 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(Me)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 84 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[(Me)Phe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 85 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[(Me)Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 86 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(Me)Lys]-[Cys]-$NH_2$; |
| 87 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[(Me)Cys]-$NH_2$; |
| 88 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-L-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 89 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Leu]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 90 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Leu]-[Cys]-$NH_2$; |
| 91 | Isovaleric Acid-[(OMe)Glu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 92 | Isovaleric Acid-[(OMe)Glu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[Lys(Ac)]-[Cys]-$NH_2$; |
| 93 | Isovaleric Acid-E-T-H-[Dpa]-P-[(D)Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 94 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[(D)Cys]-$NH_2$; |
| 95 | Isovaleric Acid-E-T-H-[Dpa]-P-[(D)Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[(D)Cys]-$NH_2$; |
| 96 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys_IVA)]-[Cys]-$NH_2$; |
| 97 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys_IVA)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 98 | [Diacid_C18_isoGlu_PEG2_PEG2]-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 99 | [C18_diacid_Ahx_PEG2_PEG2]-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 100 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-H-[(D)Phe]-R-W-[Cys]-$NH_2$; |
| 101 | Isovaleric Acid-E-T-H-F-P-[Cys]-I-Z_minus-F-E-P-R-S-K-G-[Cys]-K-$NH_2$; |
| 102 | Isovaleric Acid-[(Me)Glu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 103 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Palm)]-[bhPhe]-L-[(D)Lys]-[Cys]-$NH_2$; |
| 104 | Isovaleric Acid-[(OMe)Glu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[Cys]-$NH_2$; |
| 105 | Isovaleric Acid-[(OMe)Glu]-T-H-[Dpa]-P-[Cys]-I-[bhPhe]-[Lys(Ahx_Palm)]-[Lys(Ac)]-[Cys]-$NH_2$; |
| 106 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys_IVA)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys_IVA)]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 107 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 108 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C14_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 109 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C16_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 110 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 111 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C20_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 112 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C18)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 113 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 114 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 115 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg4_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 116 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 117 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg8_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 118 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 119 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 120 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 121 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-NH2; |
| 122 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-E-NH2; |
| 123 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-[(D)Glu]-NH2; |
| 124 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-D-NH2; |
| 125 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-[(D)Asp]-NH2; |
| 126 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-Gla-NH2; |
| 127 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-[Tet1]-NH2; |
| 128 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-[Tet2]-NH2; |
| 129 | Isovaleric Acid-E-T-H-[Dpa]-[bhPro]-[Lys(Ahx_Palm)]-[bhPhe]-NH2; |
| 130 | $Me_2$-$(CH_2)_2$-NH-C(O)-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-NH2; |
| 131 | Isovaleric Acid-[N-(CH2CH2CH2CO2H)Gly]-T-H-[Dpa]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-NH2; |
| 132 | Isovaleric Acid-E-T-H-[N-(CH2CH2C(Ph)2)Gly]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-NH2; |
| 133 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-[N-(isopentyl)Gly]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 134 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-(CH2CH2Ph)Gly]-[(D)Lys]-[Cys]-NH2; |
| 135 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[N-((CH2)5NH2)Gly]-[Cys]-NH2; |
| | |
| 201 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx)]-[bhPhe]-R-C-NH2; |
| 202 | Isovaleric Acid-E-T-[His_1Me]-[Dpa]-P-C-I-[Lys(PEG12_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 203 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-A-[(D)Lys]-C-NH2; |
| 204 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG8_Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 205 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 206 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 207 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-[Sarc]-C-NH2; |
| 208 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-L-C-NH2; |
| 209 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-F-C-NH2; |
| 210 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-G-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 211 | Isovaleric Acid-E-T-H-F-P-C-I-K-F-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-P-R-S-K-G-[Pen]-K-NH2; |
| 212 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-T |
| 213 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-E |
| 214 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-[Lys(Ac)]-G-C-T |
| 215 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-[Lys(Ac)]-G-C-E |
| 218 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-C-NH2 |
| 220 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 221 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 222 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 223 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(Ahx_Palm)]-F-E-P-R-S-K-G-C-K-NH2; |
| 224 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 225 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-R-S-K-G-C-NH2; |
| 226 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-R-S-G-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 227 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-[(D)Arg]-S-K-G-C-K-NH2; |
| 228 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-[Lys(Ac)]-S-K-G-C-K-NH2; |
| 229 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-[Lys(Ac)]-S-K-G-[Pen]-K-NH2; |
| 230 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-[Lys(Ac)]-S-G-C-NH2; |
| 231 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(IsoGlu_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 232 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C16_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 233 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C14_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 234 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C12_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 235 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C10_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 236 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 237 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG4_PEG4_IsoGlu_C18_Diacid)]-[bhF]-[(D)Lys]-C-NH2; |
| 238 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG8_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 239 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG4_IsoGlu_C18_Diacid)]-[bhF]-[(D)Lys]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 240 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(IsoGlu_C18_Diacid)]-[bhF]-[(D)Lys]-C-NH2; |
| 241 | Octanoic_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 242 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C16_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 243 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C14_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 244 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C12_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 245 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C10_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 246 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C16_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 247 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C14_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 248 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C12_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 249 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C10_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 254 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_1PEG2_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 255 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2; |
| 256 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG7_OMe)]-C-NH2; |
| 257 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG3_OMe)]-C-NH2; |
| 259 | Butyric_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 260 | Cyclohexanecarboxylic_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 261 | Heptanoic_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 263 | Hexanoic_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 264 | Valeric_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 265 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C16_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 266 | Isovaleric Acid-bE-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 267 | Isovaleric Acid-bhE-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 268 | Isovaleric Acid-Gla-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 269 | Isovaleric Acid-meE-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 271 | Isovaleric Acid-E-T-H-[Phe(2,3-diF]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 272 | Isovaleric Acid-E-T-H-[Dpa]-[Npc]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 273 | Isovaleric Acid-E-T-H-[Dpa]-[bhPhe]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 274 | Isovaleric Acid-E-T-H-[Dpa]-[PropanoicP]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 275 | Isovaleric Acid-E-T-H-[Dpa]-[ButanoicP]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 276 | Isovaleric Acid-E-T-H-[Dpa]-[Pro(4,4-diF)]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 277 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 278 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 279 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 280 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 281 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 282 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm-(D)Lys_Acrylamide)]-C-NH2; |
| 283 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys(Acrylamide)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2; |
| 284 | Acrylic_Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)-[(D)Lys]-C-NH2; |
| 285 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[Lys(PEG11_OMe)]-C-NH2; |
| 286 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[Lys(PEG11_OMe)]-C-NH2; |
| 287 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG11_OMe-[bhPhe]-[Lys(Ahx_Palm)]-[Lys(PEG11_OMe)]-C-NH2; |
| 288 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys(PEG11_OMe-[bhPhe]-[Lys(IsoGlu_Palm)]-[(D)Lys(PEG11_OMe)]-C-NH2; |
| 289 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_OMe-[bhPhe]-[(D)Lys]-C-NH2; |
| 290 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(Ac-C-NH2; |
| 291 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_IsoGlu_Palm)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2; |
| 292 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2; |
| 293 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 294 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_Palm)]-[bhPhe]-[Lys(PEG30K)]-R-C-NH2; |
| 295 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_Palm)]-[bhPhe]-[Lys(PEG40KB)]-R-C-NH2; |
| 296 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG40KB)]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2; |
| 297 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG40KB-C-NH2; |
| 298 | Isovaleric Acid-[(D)Glu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 299 | Isovaleric Acid-[IsoGlu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 300 | Isovaleric Acid-[(D)IsoGlu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 301 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_C18_Diacid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 302 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_Ahx_C18_Diacid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 303 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_C18 acid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 304 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_Ahx_C18 acid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 305 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_C18_Diacid)]-F-E-P-R-S-K-G-Abu-K-NH2; |
| 306 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18 acid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 307 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_Ahx_C18 acid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 308 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-Abu-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 309 | Isovaleric_Acid-IsoGlu-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 310 | Isovaleric Acid-[(D)Glu]-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 311 | Isovaleric_Acid-dIsoGlu-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 312 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys(PEG20K)]-C-NH2; |
| 313 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys(PEG20K)]-R-C-NH2; |
| 314 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_Palm)]-[bhPhe]-[(D)Lys(PEG20K-C-NH2; |
| 315 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 316 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 317 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(IsoGlu_Palm)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 318 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 319 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 320 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_C18)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 321 | Isovaleric Acid-[Glu_OMe]-T-His_1Me-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 322 | Isovaleric Acid-[MeGlu]-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 323 | IsovalerAldehyde-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 324 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 325 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys(Gal)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2; |
| 326 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Gal)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2; |
| 327 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys(Gal)]-C-NH2; |
| 328 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys(Gal)-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2; |
| 329 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Gal)]-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2; |
| 330 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]- [(D)Lys(Gal)]-C-NH2; |
| 331 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[meLys]-[bhPhe]-[Lys(Ahx_Palm)]-[meLys]-[Cys]-NH2; |
| 332 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-[Cys]-I-[meK]-[bhPhe]-[Lys(Ahx_Palm)]-[meLys]-[Cys]-NH2; |
| 333 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[(D)Lys]-[Cys]-NH2; |
| 334 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[(D)Lys]-[Cys]-NH2; |
| 335 | [Betaine]-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-NH2; |
| 336 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Betaine)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-NH2; |
| | |
| REF1 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| REF2 | [Isovaleric Acid]-E-T-[2Pal]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 601 | [Isovaleric Acid]-E-T-[3Quin]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 602 | [Isovaleric Acid]-E-T-[Dab]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 603 | [Isovaleric Acid]-E-T-[Dap]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 604 | [Isovaleric Acid]-E-T-[Orn]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 605 | [Isovaleric Acid]-E-S-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 606 | [Isovaleric Acid]-E-[Dap]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 607 | [Isovaleric Acid]-E-[(D)Asp]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 608 | [Isovaleric Acid]-E-S-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2 |
| 609 | [Isovaleric Acid]-E-[(D)Ser]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2 |
| 610 | [Isovaleric Acid]-E-[Dab]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2 |
| 611 | [Isovaleric Acid]-E-S-H-[Dpa]-P-C-I-[(D)Lys]-[aMePhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2 |
| 612 | [Isovaleric Acid]-E-A-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 613 | [Isovaleric Acid]-E-T-A-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 614 | [Isovaleric Acid]-E-T-A-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 615 | [Isovaleric Acid]-E-[N-MeThr]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 616 | [Isovaleric Acid]-E-T-[N-MeHis]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 617 | [Isovaleric Acid]-E-L-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 618 | [Isovaleric Acid]-E-T-L-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 619 | [Isovaleric Acid]-E-[Hyp]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 620 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 621 | [Isovaleric Acid]-E-T-[2Pal]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 622 | Isovaleric Acid-[Tet1]-T-[His_1Me]-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys]-[Cys]-NH2 |
| 623 | Isovaleric Acid-[Tet1]-T-[His_1Me]-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys]-[Cys]-E-NH2 |
| | |
| 401 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Tyr]-NH2 |
| 402 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Ser]-NH2 |
| 403 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Gln]-NH2 |
| 404 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[1Nal]-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 405 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Leu]-NH2 |
| 406 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Phe]-NH2 |
| 407 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MePhe]-NH2 |
| 408 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Cyclohexanoic_Acid)]-C-NH2 |
| 409 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Glutaric Acid)]-C-NH2 |
| 410 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Imidazol_AceticAcid)]-C-NH2 |
| 411 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Butanoic_Acid_3OH)]-C-NH2 |
| 412 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(DIP_CH2CO2H)]-C-NH2 |
| 413 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Phenylacetic_Acid_4F)]-C-NH2 |
| 414 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Ahx)]-C-NH2 |
| 415 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(IVA)]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 416 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid_Me)]-[bhPhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 417 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 418 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-NMe_Ile-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 419 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 420 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-NMe_Ile-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 421 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 422 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 423 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-NMe_Ile-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 424 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MeTyr]-NH2 |
| 425 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MeSer]-NH2 |
| 426 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MeGln]-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 427 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[2Nal]-NH2 |
| 428 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MeLeu]-NH2 |
| 429 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys_PEG15_OMe]-C-NH2 |
| 430 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG23_OMe)]-C-NH2 |
| 431 | [Isovaleric Acid]-E-T-H-[Dpa]-P-[N-MeCys]-NMe_Ile-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[N-Me(D)Lys(PEG11_OMe)]-[N-MeCys]-NH2 |
| 432 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[Dpa]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 433 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[aMePhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 434 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-[bhPro]-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 435 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-[Npc]-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 436 | [Isovaleric Acid]-E-T-H-[Dpa]-P-[N-MeCys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-[N-MeCys]-NH2 |
| 437 | [Isovaleric Acid]-E-T-H-[Dpa]-P-[aMeCys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-[aMeCys]-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 438 | [Isovaleric Acid]-E-T-[Trp(5-OH)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 439 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 440 | [Isovaleric Acid]-E-T-[Phe(4-CF3)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 441 | [Isovaleric Acid]-E-T-[Trp(6-OMe)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 442 | [Isovaleric Acid]-E-T-[Trp(5-OH)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 443 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 444 | [Isovaleric Acid]-E-T-[Phe(4-CF3)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 445 | [Isovaleric Acid]-E-T-[Trp(6-OMe)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 446 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Tle]-C-NH2 |
| 447 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Tle]-C-NH2 |
| 448 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[N-MeIle]-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[N-MeLys]-C-NH2 |
| 449 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[N-MeIle]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[N-MePhe]-[(D)Lys]-C-NH2 |
| 450 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[N-MeLys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 451 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 452 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[Dpa]-[(D)Lys]-C-NH2 |
| 453 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[Dpa]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 454 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-[Npc]-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 455 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-[Npc]-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 456 | [4-Fluorophenylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-OH |
| 457 | [Isovaleric Acid]-E-T-[2Quin]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG12_OMe)]-C-NH2 |
| 458 | [4-Fluorophenylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG12_OMe)]-C-NH2 |
| 459 | [Cyclopentylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 460 | [Isovaleric Acid]-E-T-[Bip]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG12_OMe)]-C-NH2 |
| 461 | [Cyclopentylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG12_OMe)]-C-NH2 |
| 462 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 463 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG36_Ahx_Palm)]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 464 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG36_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 465 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG24_PEG24_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 466 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG24_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 467 | [Isovaleric Acid]-E-T-Y-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 468 | [Isovaleric Acid]-E-T-W-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 469 | [Isovaleric Acid]-E-T-W-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 470 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx_Palm)]-C-NH2 |
| 471 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(PEG12_Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 472 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_PEG12_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 473 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(PEG12_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 474 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-[(D)Arg]-NH2 |
| 475 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 476 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 477 | [Isovaleric Acid]-E-T-Y-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 478 | [Isovaleric Acid]-E-T-H-F-P-C-I-[Lys(Ac)]-F-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 479 | [Isovaleric Acid]-E-T-[3Quin]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 480 | [Isovaleric Acid]-E-T-[Bip]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 481 | [4-Fluorophenylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 482 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Lys(Me3)]-C-NH2 |
| 483 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG8_OMe)]-C-NH2 |
| 484 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG8_OMe)]-C-NH2 |
| 485 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 486 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_DMG_N_2am_C18_Diacid)]-[bhPhe]-[(D)Lys(Betaine)]-C-NH2 |
| 487 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_DMG_N_2am_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 488 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_ParaBenzoate_Hydroxyl_10C_Acid)]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_ParaBenzoate_Hydroxyl_10C_Acid)]-[(D)Lys]-C-NH2 |
| 489 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_ParaBenzoate_Hydroxyl_10C_Acid)]-[bhPhe]-[(D)Lys]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 490 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_ParaBenzoate_Hydroxyl_10C_Acid)]-[(D)Lys]-C-NH2 |
| 491 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_MetaBenzoate_Hydroxyl_9C_Acid)]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_MetaBenzoate_Hydroxyl_9C_Acid)]-[(D)Lys]-C-NH2 |
| 492 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_MetaBenzoate_Hydroxyl_9C_Acid)]-[bhPhe]-[(D)Lys]-[(D)Lys]-C-NH2 |
| 493 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_MetaBenzoate_Hydroxyl_9C_Acid)]-[(D)Lys]-C-NH2 |
| 494 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-[(D)Cys]-I-[(D)Lys]-[bhPhe]-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[(D)Lys]-C-NH2 |
| 495 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-[(D)Cys]-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 498 | [Isovaleric Acid]-[Glu(OMe)]-T-W-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 500 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-[(D)Arg]-NH2 |
| 501 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 502 | [Isovaleric Acid]-[Dap]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 503 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Phe(4-COOH)]-[(D)Lys]-C-NH2 |
| 504 | [Isovaleric Acid]-[IsoGlu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 505 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe(4-Me)]-[(D)Lys]-C-NH2 |
| 506 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Aic]-[(D)Lys]-C-NH2 |
| 507 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Achc]-[(D)Lys]-C-NH2 |
| 508 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Hph]-[(D)Lys]-C-NH2 |
| 509 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[hLeu]-[(D)Lys]-C-NH2 |
| 510 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-F-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 511 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[Cha]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 512 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[Achc]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 513 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[aMeLeu]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 514 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[Tle]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 515 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[hLeu]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 516 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_PEG12_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 517 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 518 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(Ac)]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 519 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(PEG12_PEG12_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 520 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(PEG12_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 521 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(Ac)]-C-NH2 |
| 522 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Igl]-[(D)Lys]-C-NH2 |
| 523 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 524 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 525 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(DMG_N_2ae_Palm)]-[(D)Lys]-C-NH2 |
| 526 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(DMG_N_2ae_Palm)]-[(D)Lys]-C-NH2 |
| 527 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_DMG_N_2ae_Palm)]-[(D)Lys]-C-NH2 |
| 528 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_DMG_N_2ae_Palm)]-[(D)Lys]-C-NH2 |
| 529 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_DMG_N_2ae_Palm)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 530 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(PEG12_DMG_N_2ae_Palm)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 531 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_DMG_N_2ae_Palm)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 532 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(Ahx_DMG_N_2ae_Palm)]-[bhPhe]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 533 | [Isovaleric Acid]-[IsoGlu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 534 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-[(D)Arg]-NH2 |
| 535 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Arg]-C-NH2 |
| 536 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[(D)Arg]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 537 | [Isovaleric Acid]-[(D)Arg]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 538 | [Isovaleric Acid]-[Dap]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 539 | [Isovaleric Acid]-[(D)IsoGlu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 540 | [Isovaleric Acid]-[(D)Glu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 541 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[N-MeLys(Ahx_Palm)]-[(D)Lys(Carnitine)]-C-NH2 |
| 542 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(Ahx_Palm)]-[bhPhe]-[(D)Lys(Carnitine)]-C-NH2 |
| 543 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys(Carnitine)]-C-NH2 |
| 544 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 545 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 546 | [Isovaleric Acid]-E-[Dab]-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 547 | [Isovaleric Acid]-E-[Dap]-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 548 | [Isovaleric Acid]-E-[Dab]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 549 | [Isovaleric Acid]-E-[Dap]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 550 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[Amb]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 551 | [Isovaleric Acid]-E-[Lys(Acrylamide)]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 552 | [Isovaleric Acid]-E-T-[Lys(Acrylamide)]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 553 | [Isovaleric Acid]-E-T-H-[Lys(Acrylamide)]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 554 | [Isovaleric Acid]-E-T-H-[Dpa]-[Lys(Acrylamide)]-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 555 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[(D)Lys(Acrylamide)]-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 556 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[Lys(Acrylamide)]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 557 | [Isovaleric Acid]-[Dap]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 558 | [Isovaleric Acid]-E-T-H-[Dpa]-S-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 559 | [Octanoic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 560 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[(D)Lys(Gal)]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 561 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[Lys(Gal)]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 562 | [Cyclohexanoic Acid]-E-T-H-[Dpa]-P-C-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 563 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-C-OH |
| 564 | [Isovaleric Acid]-E-T-[N-(Imidazolethyl)Gly]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 565 | [Isovaleric Acid]-E-[N-(hydroxyethyl)Gly]-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 566 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[Amb]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 567 | [Isovaleric Acid]-E-T-H-[Dpa]-[N-MeAla]-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 568 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-L-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 569 | [Isovaleric Acid]-E-T-H-[Dpa]-L-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 570 | [Isovaleric Acid]-E-T-H-L-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 571 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 572 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-A-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 573 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-A-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 574 | [Isovaleric Acid]-E-T-H-[Dpa]-A-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 575 | [Isovaleric Acid]-E-T-H-A-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 576 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-K-[bhPhe]-R-C-NH2 |
| 577 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-C-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-NH2 |

**[0008e]** In another aspect, the present disclosure provides a pharmaceutical composition comprising the hepcidin analogue or pharmaceutically acceptable salt or solvate thereof or peptide of the disclosure, and a pharmaceutically acceptable carrier, excipient or vehicle.

**[0008f]** In another aspect, the present disclosure provides a method of binding a ferroportin or inducing ferroportin internalization and degradation, comprising contacting the ferroportin with at least one hepcidin analogue or pharmaceutically acceptable salt or solvate thereof or peptide of the disclosure.

**[0008g]** In another aspect, the present disclosure provides a use of the hepcidin analog or pharmaceutically acceptable salt or solvate thereof of the disclosure or the pharmaceutical composition of the disclosure in the manufacture of a medicament for (a) treating a disease of iron metabolism; or (b) treating a disease or disorder associated with dysregulated hepcidin signaling, optionally wherein the disease or disorder is a disease of iron metabolism such as an iron overload disease, hemochromatosis, a thalassemia, or a polycythemia vera.

**[0009]** In one example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (I):

$$R^1\text{-Xbb1-Thr-His-B1-B2-B3-B4-Xaa1-B6-Xaa2-J-Y1-Y2-}R^2 \quad \text{(I)}$$

or a peptide dimer comprising two peptides according to Formula I, or a pharmaceutically acceptable salt, or a solvate thereof,

wherein:

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is isoAsp, Asp(OMe), Gly, substituted Gly, Glu, substituted Glu, bhGlu, bGlu, Gla, or Glp;
each Xaa1 and Xaa2 is independently Gly, N-substituted Gly, Lys, (D)Lys, Lys(Ac), or (D)Lys(Ac);

or

Xaa1 is B5; and B5 is absent, Lys, D-Lys, (D)Leu, (D)Ala, or Lys(Ac); and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys;

or

Xaa1 is B5(L1Z); B5 is Lys, D-Lys, or Lys(Ac); and Xaa2 is B7; and B7 is Glu or absent;

each of B1 and B6 is independently Gly, substituted Gly, Phe, substituted Phe, Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;
B2 is Pro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;
B3 is Cys, homoCys, (D)Cys, a-MeCys, or Pen;
B4 is Gly, N-substituted Gly, Ile, (Me)Ile, Val, Leu, or NLeu;
L1 is absent, Dapa, D-Dapa, or isoGlu, PEG, Ahx, isoGlu-PEG, PEG-isoGlu, PEG-Ahx, isoGlu-Ahx, or isoGlu-PEG-Ahx; Ahx is an aminohexanoic acid moiety; PEG is –[C(O)-$CH_2$-$(Peg)_n$-N(H)]$_m$-, or –[C(O)-$CH_2$-$CH_2$-$(Peg)_n$-N(H)]$_m$-; and Peg is -$OCH_2CH_2$-, m is 1, 2, or 3; and n is an integer between 1-100K;
Z is a half-life extension moiety;

J is Lys, D-Lys, Arg, Pro, Pro-Arg, Pro-Lys, Pro-(D)Lys, Pro-Arg-Ser, Pro-Arg-Ser-Lys- (SEQ ID NO:249), Pro-Arg-Ser-Lys-Sar (SEQ ID NO:250), Pro-Arg-Ser-Lys-Gly (SEQ ID NO:251), His-(D)Phe-Arg-Trp, or absent; or J is any amino acid;

Y1 is Cys, homoCys, (D)Cys, NMeCys, aMeCys, or Pen;

Y2 is an amino acid or absent;

Dapa is diaminopropanoic acid, Dpa or DIP is 3,3-diphenylalanine or b,b-diphenylalanine, bhPhe is b-homophenylalanine, Bip is biphenylalanine, bhPro is b-homoproline, Tic is L-1,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid, NPC is L-nipecotic acid, bhTrp is b-homoTryptophane, 1-Nal is 1-naphthylalanine, 2-Nal is 2-naphthylalanine, Orn is orinithine, Nleu is norleucine, Abu is 2-aminobutyric acid, 2Pal is 2-pyridylalanine, Pen is penicillamine;

substituted Phe is phenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted bhPhe is b-homophenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted Trp is N-methyl-L-tryptophan, a-methyltryptophan, or tryptophan substituted with F, Cl, OH, or t-Bu;

substituted bhTrp is N-methyl-L-b-homotryptophan, a-methyl-b-homotryptophan, or b-homotryptophan substituted with F, Cl, OH, or t-Bu;

wherein

i) the peptide of formula I is optionally PEGylated on one or more $R^1$, B1, B2, B3, B4, B5, B6, B7, J, Y1, Y2, or R2; and

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1.

**[0010]** In one example, the half-life extension moiety is $C_{10}$-$C_{21}$ alkanoyl.

**[0011]** In one example, Xaa1 is B5; B5 is absent, Lys, or D-Lys; and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys.

**[0012]** In another example, Xaa1 is B5(L1Z); B5 is Lys, or D-Lys; and Xaa2 is B7; and B7 is Glu or absent.

**[0013]** In one example, Xaa1 is Lys(Ac) and Xaa2 is (D)Lys(Ac).

**[0014]** In another example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (A-I):

$$R^1\text{-Xbb1-Thr-His-B1-B2-B3-B4-B5-B6-B7(L1Z)-J-Y1-Y2-}R^2 \quad \text{(A-I)}$$

or a peptide dimer comprising two peptides according to Formula A-I, or a pharmaceutically acceptable salt, or a solvate thereof,

wherein:

$R^1$, $R^2$, B1-B6, L1, Z, J, Y1, and Y2 are as described for Formula (I);

B7 is Lys, or D-Lys;

wherein

i) the peptide of formula I is optionally PEGylated on one or more $R^1$, B1, B2, B3, B4, B5, B6, J, Y1, Y2, or R2;

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1;

iii) when the peptide is a peptide dimer, then B7(L1Z)-J-Y1-Y2 is absent;

iv) when the peptide is a peptide dimer, the peptide dimer is dimerized

a) via a linker moiety,

b) via an intermolecular disulfide bond between two B3 residues, one in each monomer subunit, or

c) via both a linker moiety and an intermolecular disulfide bond between two B3 residues; and

d) the linker moiety comprises a half-life extending moiety.

**[0015]** In one example, the half-life extension moiety is $C_{10}$-$C_{21}$ alkanoyl.

**[0016]** In another example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (B-I):

$$R^1\text{-Xbb1-Thr-His-B1-B2-B3-B4-B5(L1Z)-B6-B7-J-Y1-Y2-}R^2 \quad \text{(B-I)}$$

or a peptide dimer comprising two peptides according to Formula B-I, or a pharmaceutically acceptable salt, or a solvate thereof,

wherein:

$R^1$, $R^2$, B1-B6, L1, Z, J, Y1, and Y2 are as described for Formula (I);

wherein

i) the peptide of formula I is optionally PEGylated on one or more $R^1$, B1, B2, B3, B4, B6, B7, J, Y1, Y2, or R2; and

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1; and

iii) when B6 is Phe, Y1 is Cys, and Y2 is Lys, then J is Pro, Arg, Gly, Pro-Arg, Pro-Lys, Pro-(D)Lys, Pro-Arg-Ser, Pro-Arg-Ser-Lys (SEQ ID NO:249), or absent.

**[0017]** In one example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (I'):

$$R^1\text{-Xbb1-Thr-X3-B1-B2-B3-B4-Xaa1-B6-Xaa2-J-Y1-Y2-}R^2 \quad (I')$$

or a pharmaceutically acceptable salt or solvate thereof,

wherein:

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, $C_2$-$C_{20}$ alkenoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is Asp, isoAsp, Asp(OMe), Gly, substituted Gly, Glu, substituted Glu, isoGlu, (D)Glu, (D)isoGlu, bhGlu, bGlu, Gla, or Glp;

X3 is His or substituted His;

each Xaa1 and Xaa2 is independently Ala, Gly, N-substituted Gly, Lys, (D)Lys, Lys(Ac), or (D)Lys(Ac);

or

Xaa1 is B5; and B5 is absent, Lys, D-Lys, (D)Leu, (D)Ala, a-Me-Lys, or Lys(Ac); and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys;

or

Xaa1 is B5(L1Z); B5 is Lys, D-Lys, or Lys(Ac); and Xaa2 is B7; and B7 is Glu or absent;

each of B1 and B6 is independently Gly, substituted Gly, Phe, substituted Phe, Dpa, substituted Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;

B2 is Pro, substituted Pro, propanoicPro, butanoicPro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;

B3 is Cys, homoCys, (D)Cys, a-MeCys, or Pen;

B4 is Gly, N-substituted Gly, Ile, (Me)Ile, Val, Leu, or NLeu;

L1 is absent, Dapa, D-Dapa, or isoGlu, PEG, Ahx, isoGlu-PEG, isoGlu-PEG, PEG-Ahx, isoGlu-Ahx, or isoGlu-PEG-Ahx;

wherein Ahx is an aminohexanoic acid moiety; PEG is $[C(O)-CH_2-(Peg)_n-N(H)]_m$, or $[C(O)-CH_2-CH_2-(Peg)_n-N(H)]_m$; and Peg is $OCH_2CH_2$, m is 1, 2, or 3; and n is an integer between 1-100K;

Z is a half-life extension moiety;

J is absent, any amino acid, or a peptide chain consisting of 1-5 amino acids, wherein each amino acid is independently selected from Pro, (D)Pro, hydroxyPro, hydroxy(D)Pro, Arg, MeArg, Lys, (D)Lys, Lys(Ac), (D)Lys(Ac), Ser, MeSer, Sar, and Gly;

Y1 is Abu, Cys, homoCys, (D)Cys, NMeCys, aMeCys, or Pen;

Y2 is an amino acid or absent;

Dapa is diaminopropanoic acid, Dpa or DIP is 3,3-diphenylalanine or b,b-diphenylalanine, bhPhe is b-homophenylalanine, Bip is biphenylalanine, bhPro is b-homoproline, Tic is L-1,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid, NPC is L-nipecotic acid, bhTrp is b-homoTryptophane, 1-Nal is 1-naphthylalanine, 2-Nal is 2-naphthylalanine, Orn is orinithine, Nleu is norleucine, Abu is 2-aminobutyric acid, 2Pal is 2-pyridylalanine, Pen is penicillamine;

substituted Phe is phenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted bhPhe is b-homophenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted Trp is N-methyl-L-tryptophan, a-methyltryptophan, or tryptophan substituted with F, Cl, OH, or t-Bu; and

substituted bhTrp is N-methyl-L-b-homotryptophan, a-methyl-b-homotryptophan, or b-homotryptophan substituted with F, Cl, OH, or t-Bu;

wherein

i) the peptide of formula I is optionally PEGylated on one or more of $R^1$, B1, B2, B3, B4, B5, B6, B7, J, Y1, Y2, or R2; and

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1;

provided that when Xbb1 is Asp, then $R^1$ is $C_2$-$C_{20}$ alkenoyl.

**[0018]** In one example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (XXI):

$R^1$-Xbb1-Thr-His-B1-B2-Cys-Ile-B5(L1Z)-B6-B7-J-Y1-Y2-$R^2$ (XXI)

wherein:

L1, Z, J, Y1, and Y2 are as described for Formula (I);

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, $C_2$-$C_{20}$ alkenoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is Glu, substituted Glu, IsoGlu, (D)Glu, (D)isoGlu, bhGlu, or bGlu;

each of B1 and B6 is independently Phe, substituted Phe, Dpa, substituted Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;

B2 is Pro, substituted Pro, propanoicPro, butanoicPro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;

B5 is Lys or (D)Lys; and

B7 is Glu or absent.

**[0019]** In one example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (XXII):

$R^1$-Xbb1-Thr-His-B1-B2-Cys-Ile-B5(L1Z)-B6-B7(L1Z)-J-Y1-Y2-$R^2$ (XXII)

wherein:

L1, Z, J, Y1, and Y2 are as described for Formula (I);

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, $C_2$-$C_{20}$ alkenoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is Glu, substituted Glu, IsoGlu, (D)Glu, (D)isoGlu, bhGlu, or bGlu;

each of B1 and B6 is independently Phe, substituted Phe, Dpa, substituted Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;

B2 is Pro, substituted Pro, propanoicPro, butanoicPro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;

B5 is Lys or (D)Lys; and

B7 is Lys or (D)Lys.

**[0020]** In particular examples, -L1Z is:

-PEG11_OMe;

-PEG12_ C18 acid;

-1PEG2_1PEG2_Ahx_Palm;

-1PEG2_Ahx_Palm;

-Ado_Palm;

-Ahx_Palm;

-Ahx_PEG20K;

-PEG12_Ahx_IsoGlu_Behenic;

-PEG12_Ahx_Palm;

-PEG12_DEKHKS_Palm;

-PEG12_IsoGlu_C18 acid;

-PEG12_Ahx_C18 acid;

-PEG12_IsoGlu_Palm;

-PEG12_KKK_Palm;

-PEG12_KKKG_Palm;

-PEG12_DEKHKS_Palm;

-PEG12_Palm;

-PEG12_PEG12_Palm;

-PEG20K;

-PEG4_Ahx_Palm;

-PEG4_Palm;

-PEG8_Ahx_Palm; or

-IsoGlu_Palm;

-1PEG2_1PEG2_Dap_C18_Diacid;

-1PEG2_1PEG2_IsoGlu_C10_Diacid;

-1PEG2_1PEG2_IsoGlu_C12_Diacid;

-1PEG2_1PEG2_IsoGlu_C14_Diacid;

-1PEG2_1PEG2_IsoGlu_C16_Diacid;

-1PEG2_1PEG2_IsoGlu_C18_Diacid;

-1PEG2_1PEG2_IsoGlu_C22_Diacid;

-1PEG2_1PEG2_Ahx_C18_Diacid;

-1PEG2_1PEG2_ C18_Diacid;

-1PEG8_IsoGlu_C18_Diacid;

-IsoGlu_C18_Diacid;

-PEG12_Ahx_C18_Diacid;

-PEG12_C16_Diacid;

-PEG12_C18_Diacid;

-1PEG2_1PEG2_1PEG2_ C18_Diacid;

-1PEG2_1PEG2_1PEG2_ IsoGlu_C18_Diacid;

-PEG12_IsoGlu_C18_Diacid;

-PEG4_IsoGlu_C18_Diacid; or

-PEG4_PEG4_IsoGlu_C18_Diacid;

wherein

PEG11_OMe is –[C(O)-$CH_2$-$CH_2$–$(OCH_2CH_2)_{11}$-OMe];

1PEG2 is –C(O)-$CH_2$–$(OCH_2CH_2)_2$-NH-;

PEG4 is –C(O)-$CH_2$-$CH_2$–$(OCH_2CH_2)_4$-NH-;

PEG8 is –[C(O)-$CH_2$-$CH_2$–$(OCH_2CH_2)_8$-NH-;

1PEG8 is –[C(O)-$CH_2$–$(OCH_2CH_2)_8$-NH-;


PEG12 is –[C(O)-$CH_2$-$CH_2$–$(OCH_2CH_2)_{12}$-NH-;

Ado is –[C(O)-$(CH_2)_{11}$-NH]-

Cn acid is -C(O)$(CH_2)_{n-2}$-$CH_3$; C18 acid is -C(O)-$(CH_2)_{16}$-Me;

Palm is -C(O)-$(CH_2)_{14}$-Me;

isoGlu is isoglutamic acid;

isoGlu_Palm is 

;

Ahx is –[C(O)-$(CH_2)_5$-NH]-;

Cn_Diacid is -C(O)-$(CH_2)_{n-2}$-COOH; wherein n is 10, 12, 14, 16, 18, or 22.

**[0021]** In particular examples of hepcidin analogues disclosed herein, the half-life extending moiety is $C_{10}$-$C_{21}$ alkanoyl.

**[0022]** In one particular example, B7 is Lys, D-Lys, homoLys, or a-Me-Lys.

**[0023]** In particular examples of any of the hepcidin analogues or dimers of the present disclosure, the linker moiety is selected from IsoGlu, Dapa, PEGn where n= 1 to 25, PEG11(40

atoms), OEG, IsoGlu-Ahx, IsoGlu-OEG-OEG, IsoGlu-PEG5, IsoGlu-PEGn, PEGn-isoGlu, PEGn-Ahx, where n= 1 to 25 βAla-PEG2, and βAla-PEG11(40 atoms). In certain examples, more than one linker moiety is conjugated to a peptide of the hepcidin analogue or dimer.

**[0024]** In one example, B5 is Lys. In another example, B7 is Lys.

**[0025]** In one example, B5 is D-Lys. In another example, B7 is D-Lys.

**[0026]** In one example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (LI):

$$R^1\text{-Xbb1-Xcc1-Xdd1-B1-B2-B3-B4-Xaa1-B6-Xaa2-J-Y1-Y2-}R^2 \quad \text{(LI)}$$

or a pharmaceutically acceptable salt, or a solvate thereof,

wherein:

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is isoAsp, Asp(OMe), Glu, bhGlu, bGlu, Gla, or Glp;

Xcc1 is any amino acid other than Thr; and Xdd1 is any amino acid; or Xcc1 is any amino acid; and Xdd1 is any amino acid other than His;

Xaa1 is B5; and

i) B5 is absent, Lys, D-Lys, or Lys(Ac); and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys;

or

ii) Xaa1 is B5(L1Z); B5 is Lys, D-Lys, or Lys(Ac); and Xaa2 is B7; and B7 is Glu or absent;

each of B1 and B6 is independently Phe, Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;

B2 is Pro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;

B3 is Cys, homoCys, (D)Cys, a-MeCys, or Pen;

B4 is Ile, Val, Leu, or NLeu;

L1 is absent, Dapa, D-Dapa, or isoGlu, PEG, Ahx, isoGlu-PEG, PEG-isoGlu, PEG-Ahx, isoGlu-Ahx, or isoGlu-PEG-Ahx; Ahx is an aminohexanoic acid moiety; PEG is $-[C(O)\text{-}CH_2\text{-}(Peg)_n\text{-}N(H)]_m$-, or $-[C(O)\text{-}CH_2\text{-}CH_2\text{-}(Peg)_n\text{-}N(H)]_m$-; and Peg is $-OCH_2CH_2$-, m is 1, 2, or 3; and n is an integer between 1-100K;

Z is a half-life extension moiety;

J is Lys, D-Lys, Arg, Pro, -Pro-Arg-, -Pro-Lys-, -Pro-(D)Lys-, -Pro-Arg-Ser-, -Pro-Arg-Ser-Lys- (SEQ ID NO:249), -Pro-Arg-Ser-Lys-Sar- (SEQ ID NO:250), -Pro-Arg-Ser-Lys-Gly- (SEQ ID NO:251), or absent; or J is any amino acid;

Y1 is Cys, homoCys, (D)Cys, NMeCys, aMeCys, or Pen; Y2 is an amino acid or absent;

Dapa is diaminopropanoic acid, Dpa or DIP is 3,3-diphenylalanine or b,b-diphenylalanine, bhPhe is b-homophenylalanine, Bip is biphenylalanine, bhPro is b-homoproline, Tic is L-1,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid, NPC is L-nipecotic acid, bhTrp is b-homoTryptophane, 1-Nal is 1-naphthylalanine, 2-Nal is 2-naphthylalanine, Orn is orinithine, Nleu is norleucine, Abu is 2-aminobutyric acid, 2Pal is 2-pyridylalanine, Pen is penicillamine;

substituted Phe is phenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted bhPhe is b-homophenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted Trp is N-methyl-L-tryptophan, a-methyltryptophan, or tryptophan substituted with F, Cl, OH, or t-Bu;

substituted bhTrp is N-methyl-L-b-homotryptophan, a-methyl-b-homotryptophan, or b-homotryptophan substituted with F, Cl, OH, or t-Bu;

wherein

i) the peptide of formula LI is optionally PEGylated on one or more $R^1$, B1, B2, B3, B4, B5, B6, B7, J, Y1, Y2, or R2; and

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1.

**[0027]** In one example, the half-life extension moiety is $C_{10}$-$C_{21}$ alkanoyl.

**[0028]** In one example, Xaa1 is B5; B5 is absent, Lys, or D-Lys; and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys.

**[0029]** In another example, Xaa1 is B5(L1Z); B5 is Lys, or D-Lys; and Xaa2 is B7; and B7 is Glu or absent.

**[0030]** In another example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (LI-AI), or (LI-A2):

$R^1$-Xbb1-Xcc1-His-B1-B2-B3-B4-B5-B6-B7(L1Z)-J-Y1-Y2-$R^2$ (LI-A1); or

$R^1$-Xbb1-Thr-Xdd1-B1-B2-B3-B4-B5-B6-B7(L1Z)-J-Y1-Y2-$R^2$ (LI-A2)

or a pharmaceutically acceptable salt, or a solvate thereof,

wherein:

Xbb1, Xcc1, Xdd1, $R^1$, $R^2$, B1-B6, L1, Z, J, Y1, and Y2 are as described for formula (LI);

B7 is Lys, or D-Lys;

wherein

i) the peptide of formula I is optionally PEGylated on one or more $R^1$, B1, B2, B3, B4, B5, B6, J, Y1, Y2, or R2;

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1;

iii) when the peptide is a peptide dimer, then B7(L1Z)-J-Y1-Y2 is absent;

iv) when the peptide is a peptide dimer, the peptide dimer is dimerized

a) via a linker moiety,

b) via an intermolecular disulfide bond between two B3 residues, one in each monomer subunit, or

c) via both a linker moiety and an intermolecular disulfide bond between two B3 residues; and

d) the linker moiety comprises a half-life extending moiety.

**[0031]** In one example, the half-life extension moiety is $C_{10}$-$C_{21}$ alkanoyl.

**[0032]** In another example, the present disclosure includes a hepcidin analogue comprising a peptide of Formula (LI-B1) or (LI-B2):

$R^1$-Xbb1-Xcc1-His-B1-B2-B3-B4-B5(L1Z)-B6-B7-J-Y1-Y2-$R^2$ (LI-B1); or

$R^1$-Xbb1-Thr-Xdd1-B1-B2-B3-B4-B5(L1Z)-B6-B7-J-Y1-Y2-$R^2$ (LI-B2)

or a pharmaceutically acceptable salt, or a solvate thereof,

wherein:

Xbb1, Xcc1, Xdd1, $R^1$, $R^2$, B1-B6, L1, Z, J, Y1, and Y2 are as described for formula (LI);

wherein

i) the peptide of formula LI is optionally PEGylated on one or more $R^1$, B1, B2, B3, B4, B6, B7, J, Y1, Y2, or R2; and

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1; and

iii) when B6 is Phe, Y1 is Cys, and Y2 is Lys, then J is Pro, Arg, Gly, -Pro-Arg-, -Pro-Lys-, -Pro-(D)Lys-, -Pro-Arg-Ser-, -Pro-Arg-Ser-Lys-(SEQ ID NO:249), or absent.

**[0033]** In particular examples of hepcidin analogues disclosed herein, the half-life extending moiety is $C_{10}$-$C_{21}$ alkanoyl.

**[0034]** In one particular example, B7 is Lys, D-Lys, homoLys, or a-Me-Lys.

**[0035]** In particular examples of any of the hepcidin analogues or dimers of the present disclosure, the linker moiety is selected from IsoGlu, Dapa, PEGn where n= 1 to 25, PEG11(40 atoms), OEG, IsoGlu-Ahx, IsoGlu-OEG-OEG, IsoGlu-PEG5, IsoGlu-PEGn, PEGn-isoGlu, PEGn-Ahx, where n= 1 to 25 βAla-PEG2, and βAla-PEG11(40 atoms). In certain examples, more than one linker moiety is conjugated to a peptide of the hepcidin analogue or dimer.

**[0036]** In one example, B5 is Lys. In another example, B7 is Lys.

**[0037]** In one example, B5 is D-Lys. In another example, B7 is D-Lys.

**[0038]** In particular examples of any of the hepcidin analogues or dimers of the present disclosure, the half-life extension moiety is selected from C12 (Lauric acid), C14 (Mysteric acid), C16(Palmitic acid), C18 (Stearic acid), C20, C12 diacid, C14 diacid, C16 diacid, C18 diacid, C20 diacid, biotin, and isovaleric acid, or a residue thereof. In certain examples, the half-life extension moiety is attached to a linker moiety that is attached to the peptide. In certain examples, the half-life extension moiety increases the molecular weight of the hepcidin analogue by about 50 D to about 2 KD. In various examples, the half-life extension moiety increases serum half-life, enhances solubility, and/or improves bioavailability of the hepcidin analogue.

**[0039]** In certain examples, a peptide analogue or dimer of the present disclosure comprises an isovaleric acid moiety conjugated to an N-terminal Asp residue.

**[0040]** In certain examples, a peptide analogue of the present disclosure comprises an amidated C-terminal residue.

**[0041]** In certain examples, the present disclosure provides hepcidin analogues, including any hepcidin analogue or peptide disclosed herein or comprising or consisting of a sequence or structure disclosed herein, including but not limited to wherein the hepcidin analogue or peptide comprises a disulfide bond between two Cys residues.

**[0042]** In certain examples, a hepcidin analogue or dimer of the present disclosure comprises the sequence: Asp-Thr-His-Phe-Pro-Cys-Ile-Lys-Phe-Glu-Pro-Arg-Ser-Lys-Gly-

Cys-Lys (SEQ ID NO:252), or comprises a sequence having at least 80%, at least 90%, or at least 94% identity to this sequence.

**[0043]** In certain examples, a hepcidin analogue or dimer of the present disclosure comprises the sequence: Asp-Thr-His-Phe-Pro-Cys-Ile-Lys-Phe-Lys-Pro-Arg-Ser-Lys-Gly-Cys-Lys (SEQ ID NO:1), or comprises a sequence having at least 80%, at least 90%, or at least 94% identity to this sequence.

**[0044]** In a related example, the present disclosure includes a polynucleotide that encodes a peptide of a hepcidin analogue or dimer (or monomer subunit of a dimer) of the present disclosure.

**[0045]** In a further related example, the present disclosure includes a vector comprising a polynucleotide of the disclosure. In particular examples, the vector is an expression vector comprising a promoter operably linked to the polynucleotide, e.g., in a manner that promotes expression of the polynucleotide.

**[0046]** In another example, the present disclosure includes a pharmaceutical composition, comprising a hepcidin analogue, dimer, polynucleotide, or vector of the present disclosure, and a pharmaceutically acceptable carrier, excipient or vehicle.

**[0047]** In another examples, the present disclosure provides a method of binding a ferroportin or inducing ferroportin internalization and degradation, comprising contacting the ferroportin with at least one hepcidin analogue, dimer or composition of the present disclosure.

**[0048]** In a further example, the present disclosure includes a method for treating a disease of iron metabolism in a subject in need thereof comprising providing to the subject an effective amount of a pharmaceutical composition of the present disclosure. In certain examples, the pharmaceutical composition is provided to the subject by an oral, intravenous, peritoneal, intradermal, subcutaneous, intramuscular, intrathecal, inhalation, vaporization, nebulization, sublingual, buccal, parenteral, rectal, vaginal, or topical route of administration. In certain examples, the pharmaceutical composition is provided to the subject by an oral or subcutaneous route of administration. In certain examples, the disease of iron metabolism is an iron overload disease. In certain examples, the pharmaceutical composition is provided to the subject at most or about twice daily, at most or about once daily, at most or about once every two days, at most or about once a week, or at most or about once a month.

**[0049]** In particular examples, the hepcidin analogue is provided to the subject at a dosage of about 1 mg to about 100 mg or about 1 mg to about 5 mg.

**[0050]** In another example, the present disclosure provides a device comprising pharmaceutical composition of the present disclosure, for delivery of a hepcidin analogue or dimer of the disclosure to a subject, optionally orally or subcutaneously.

**[0051]** In yet another example, the present disclosure includes a kit comprising a pharmaceutical composition of the disclosure, packaged with a reagent, a device, or an instructional material, or a combination thereof.

## DETAILED DESCRIPTION OF THE INVENTION

**[0052]** The present invention relates generally to hepcidin analogue peptides and methods of making and using the same. In certain embodiments, the hepcidin analogues exhibit one or more hepcidin activity. In certain embodiments, the present invention relates to hepcidin peptide analogues comprising one or more peptide subunit that forms a cyclized structures through an intramolecular bond, e.g., an intramolecular disulfide bond. In particular embodiments, the cyclized structure has increased potency and selectivity as compared to non-cyclized hepcidin peptides and analogies thereof. In particular embodiments, hepcidin analogue peptides of the present invention exhibit increased half-lives, e.g., when delivered orally, as compared to hepcidin or previous hepcidin analogues.

### Definitions and Nomenclature

**[0053]** Unless otherwise defined herein, scientific and technical terms used in this application shall have the meanings that are commonly understood by those of ordinary skill in the art. Generally, nomenclature used in connection with, and techniques of, chemistry, molecular biology, cell and cancer biology, immunology, microbiology, pharmacology, and protein and nucleic acid chemistry, described herein, are those well-known and commonly used in the art.

**[0054]** As used herein, the following terms have the meanings ascribed to them unless specified otherwise.

**[0055]** Throughout this specification, the word "comprise" or variations such as "comprises" or "comprising" will be understood to imply the inclusion of a stated integer (or components) or group of integers (or components), but not the exclusion of any other integer (or components) or group of integers (or components).

**[0056]** The singular forms "a," "an," and "the" include the plurals unless the context clearly dictates otherwise.

What is claimed is:

1. A hepcidin analogue comprising a peptide according to Formula I':

$$R^1\text{-Xbb1-Thr-X3-B1-B2-B3-B4-Xaa1-B6-Xaa2-J-Y1-Y2-}R^2 \quad (I')$$

or a pharmaceutically acceptable salt or solvate thereof,

wherein:

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, $C_2$-$C_{20}$ alkenoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is Asp, isoAsp, Asp(OMe), Gly, substituted Gly, Glu, substituted Glu, isoGlu, (D)Glu, (D)isoGlu, bhGlu, bGlu, Gla, or Glp;

X3 is His or substituted His;

each Xaa1 and Xaa2 is independently Ala, Gly, N-substituted Gly, Lys, (D)Lys, Lys(Ac), or (D)Lys(Ac); or

Xaa1 is B5; and B5 is absent, Lys, D-Lys, (D)Leu, (D)Ala, a-Me-Lys, or Lys(Ac); and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys; or

Xaa1 is B5(L1Z); B5 is Lys, D-Lys, or Lys(Ac); and Xaa2 is B7; and B7 is Glu or absent;

each of B1 and B6 is independently Gly, substituted Gly, Phe, substituted Phe, Dpa, substituted Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;

B2 is Pro, substituted Pro, propanoicPro, butanoicPro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;

B3 is Cys, homoCys, (D)Cys, a-MeCys, or Pen;

B4 is Gly, N-substituted Gly, Ile, (Me)Ile, Val, Leu, or NLeu;

L1 is absent, Dapa, D-Dapa, or isoGlu, PEG, Ahx, isoGlu-PEG, isoGlu-PEG, PEG-Ahx, isoGlu-Ahx, or isoGlu-PEG-Ahx;

wherein Ahx is an aminohexanoic acid moiety; PEG is $-[C(O)\text{-}CH_2\text{-}(Peg)_n\text{-}N(H)]_m$-, or $-[C(O)\text{-}CH_2\text{-}CH_2\text{-}(Peg)_n\text{-}N(H)]_m$-; and Peg is $-OCH_2CH_2$-, m is 1, 2, or 3; and n is an integer between 1-100K;

Z is a half-life extension moiety;

J is absent, any amino acid, or a peptide chain consisting of 1-5 amino acids, wherein each amino acid is independently selected from Pro, (D)Pro, hydroxyPro, hydroxy(D)Pro, Arg, MeArg, Lys, (D)Lys, Lys(Ac), (D)Lys(Ac), Ser, MeSer, Sar, and Gly;

Y1 is Abu, Cys, homoCys, (D)Cys, NMeCys, aMeCys, or Pen;

Y2 is an amino acid or absent;

Dapa is diaminopropanoic acid, Dpa or DIP is 3,3-diphenylalanine or b,b-diphenylalanine, bhPhe is b-homophenylalanine, Bip is biphenylalanine, bhPro is b-homoproline, Tic is L-1,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid, NPC is L-nipecotic acid, bhTrp is b-homoTryptophane, 1-Nal is 1-naphthylalanine, 2-Nal is 2-naphthylalanine, Orn is orinithine, Nleu is norleucine, Abu is 2-aminobutyric acid, 2Pal is 2-pyridylalanine, Pen is penicillamine;

substituted Phe is phenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted bhPhe is b-homophenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted Trp is N-methyl-L-tryptophan, a-methyltryptophan, or tryptophan substituted with F, Cl, OH, or t-Bu; and

substituted bhTrp is N-methyl-L-b-homotryptophan, a-methyl-b-homotryptophan, or b-homotryptophan substituted with F, Cl, OH, or t-Bu;

wherein

i) the peptide of formula I is optionally PEGylated on one or more of $R^1$, B1, B2, B3, B4, B5, B6, B7, J, Y1, Y2, or R2; and

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1;

provided that when Xbb1 is Asp, then $R^1$ is $C_2$-$C_{20}$ alkenoyl.

2. The hepcidin analogue comprising a peptide according to claim 1, wherein:

(a) Xbb1 is Asp; and $R^1$ is $C_2$-$C_{20}$ alkenoyl;

(b) Xbb1 is (D)Glu, or (D)isoGlu; or

(c) Xbb1 is isoAsp, Asp(OMe), Gly, substituted Gly, Glu, substituted Glu, bhGlu, bGlu, Gla, or Glp; or

(d) B1 is Dpa; or

(e) Xaa1 is B5(L1Z); B5 is Lys, D-Lys, Dap or Dap-Dap; and Xaa2 is B7; and B7 is Glu, or absent; or

(f) B2 is Pro, or NPC; or

(g) X7 is Ile; or

(h) B9 is Phe, or bhPhe; or

(i) J is absent, any amino acid, or a peptide chain consisting of 1-5 amino acids, wherein each amino acid is independently selected from Pro, (D)Pro, hydroxyPro, hydroxy(D)Pro, Arg, MeArg, Lys, (D)Lys, Lys(Ac), (D)Lys(Ac), Ser, MeSer, Sar, and Gly; or

(j) J is Arg, Lys, D-Lys, Spiro_pip, Arg(nitro), Arg(dimethyl), Cit, Pro(4-amino), Cav, Pro-, Pro-Arg-, -Pro-Lys-, -Pro-(D)Lys-, -Pro-Arg-Ser-, -Pro-Arg-Ser-Lys-(SEQ ID NO:249), -Pro-Arg-Ser-Lys-Sar-(SEQ ID NO:250), -Pro-Arg-Ser-Lys-Gly-(SEQ ID NO:251), -Pro-Lys(Ac)-, -Pro-(D)Lys(Ac)-, -Pro-Arg-Ser-Lys(Ac)-(SEQ ID NO:249), -Pro-Arg-Ser-Lys(Ac)-Sar-(SEQ ID NO:250), -Pro-Arg-Ser-Lys(Ac)-Gly-, -HydroxyPro-Arg-Ser-Lys-Gly- (SEQ ID NO:251), -Pro-MeArg-Ser-Lys-Gly-, -Pro-Arg-MeSer-Lys-Gly- (SEQ ID NO:251), (SEQ ID NO:251), -Pro-Lys(Ac)-Ser-Lys(Ac)-, -Pro-Lys(Ac)-Ser-Lys(Ac)-Gly-, -Pro-Lys(Ac)-Ser-Lys(Ac)-Gly-, -Pro-Lys(Ac)-Ser-Lys(Ac)-Sar-, -Pro-Arg-Ser-MeLys-Gly-, or absent; or J is any amino acid; or

(k) J is Arg, Lys, D-Lys, Spiro_pip, Arg(nitro), Arg(dimethyl), Cit, Pro(4-amino), Cav, Pro-, Pro-Arg-, -Pro-Lys-, -Pro-(D)Lys-, -Pro-Arg-Ser-, -Pro-Arg-Ser-Lys-(SEQ ID NO:249), -Pro-Arg-Ser-Lys-Sar-(SEQ ID NO:250), -Pro-Arg-Ser-Lys-Gly-(SEQ ID NO:251), or absent; or J is any amino acid.

3. A hepcidin analogue comprising a peptide according to claim 1, further according to Formula I:

$R^1$-Xbb1-Thr-His-B1-B2-B3-B4-Xaa1-B6-Xaa2-J-Y1-Y2-$R^2$ (I)

or a pharmaceutically acceptable salt or solvate thereof, wherein:

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is isoAsp, Asp(OMe), Gly, substituted Gly, Glu, substituted Glu, bhGlu, bGlu, Gla, or Glp;
each Xaa1 and Xaa2 is independently Gly, N-substituted Gly, Lys, (D)Lys, Lys(Ac), or (D)Lys(Ac); or

Xaa1 is B5; and B5 is absent, Lys, D-Lys, (D)Leu, (D)Ala, or Lys(Ac); and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys; or

Xaa1 is B5(L1Z); B5 is Lys, D-Lys, or Lys(Ac); and Xaa2 is B7; and B7 is Glu or absent;

each of B1 and B6 is independently Gly, substituted Gly, Phe, substituted Phe, Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;

B2 is Pro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;
B3 is Cys, homoCys, (D)Cys, a-MeCys, or Pen;
B4 is Gly, N-substituted Gly, Ile, (Me)Ile, Val, Leu, or NLeu;
L1 is absent, Dapa, D-Dapa, or isoGlu, PEG, Ahx, isoGlu-PEG, isoGlu-PEG, PEG-Ahx, isoGlu-Ahx, or isoGlu-PEG-Ahx;
wherein Ahx is an aminohexanoic acid moiety; PEG is $–[C(O)-CH_2-(Peg)_n-N(H)]_m-$, or $–[C(O)-CH_2-CH_2-(Peg)_n-N(H)]_m-$; and Peg is $-OCH_2CH_2-$, m is 1, 2, or 3; and n is an integer between 1-100K;
Z is a half-life extension moiety;
J is Lys, D-Lys, Arg, Pro, -Pro-Arg-, -Pro-Lys-, -Pro-(D)Lys-, -Pro-Arg-Ser-, -Pro-Arg-Ser-Lys-(SEQ ID NO:249), -Pro-Arg-Ser-Lys-Sar-(SEQ ID NO:250), -Pro-Arg-Ser-Lys-Gly-(SEQ ID NO:251), -His-(D)Phe-Arg-Trp-Cys-, or absent; or J is any amino acid;
Y1 is Cys, homoCys, (D)Cys, NMeCys, aMeCys, or Pen;
Y2 is an amino acid or absent;
Dapa is diaminopropanoic acid, Dpa or DIP is 3,3-diphenylalanine or b,b-diphenylalanine, bhPhe is b-homophenylalanine, Bip is biphenylalanine, bhPro is b-homoproline, Tic is L-1,2,3,4,-tetrahydro-isoquinoline-3-carboxylic acid, NPC is L-nipecotic acid, bhTrp is b-homoTryptophane, 1-Nal is 1-naphthylalanine, 2-Nal is 2-naphthylalanine, Orn is orinithine, Nleu is norleucine, Abu is 2-aminobutyric acid, 2Pal is 2-pyridylalanine, Pen is penicillamine; substituted Phe is phenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-

dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted bhPhe is b-homophenylalanine wherein phenyl is substituted with F, Cl, Br, I, OH, methoxy, dimethoxy, dichloro, dimethyl, difluoro, pentafluoro, allyloxy, azido, nitro, 4-carbamoyl-2,6-dimethyl, trifluoromethoxy, trifluoromethyl, phenoxy, benzyloxy, carbamoyl, t-Bu, carboxyl, CN, or guanidine;

substituted Trp is N-methyl-L-tryptophan, a-methyltryptophan, or tryptophan substituted with F, Cl, OH, or t-Bu; and

substituted bhTrp is N-methyl-L-b-homotryptophan, a-methyl-b-homotryptophan, or b-homotryptophan substituted with F, Cl, OH, or t-Bu;

wherein

i) the peptide of formula I is optionally PEGylated on one or more of $R^1$, B1, B2, B3, B4, B5, B6, B7, J, Y1, Y2, or R2; and

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1.

4. The hepcidin analogue or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein:

(a) each Xaa1 and Xaa2 is independently Lys, Lys(Ac), (D)Lys, or (D)Lys(Ac); or

(b) Xaa1 is Lys(Ac); and Xaa2 is (D)Lys(Ac); or

(c) Xaa1 is B5; B5 is absent, Lys, or D-Lys; and Xaa2 is B7(L1Z); and B7 is Lys, D-Lys, homoLys, or a-Me-Lys; or

(d) Xaa1 is B5(L1Z); B5 is Lys, or D-Lys; and Xaa2 is B7; and B7 is Glu or absent; or

(e) the peptide is according to Formula A-I:

$R^1$-Xbb1-Thr-His-B1-B2-B3-B4-B5-B6-B7(L1Z)-J-Y1-Y2-$R^2$ (A-I)

wherein:

$R^1$, $R^2$, B1-B6, L1, Z, J, Y1, and Y2 are as described in claim 1; and

B7 is Lys, or D-Lys;

wherein

i) the peptide is optionally PEGylated on one or more $R^1$, B1, B2, B3, B4, B5, B6, J, Y1, Y2, or R2;

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1; and

iii) when B6 is Phe, then B5 is other than Lys; or

(f) the peptide is according to Formula B-I:

$R^1$-Xbb1-Thr-His-B1-B2-B3-B4-B5(L1Z)-B6-B7-J-Y1-Y2-$R^2$ (B-I)

wherein:

$R^1$, $R^2$, B1-B6, L1, Z, J, Y1, and Y2 are as described in claim 1

wherein

i) the peptide of formula I is optionally PEGylated on one or more $R^1$, B1, B2, B3, B4, B6, B7, J, Y1, Y2, or R2; and

ii) the peptide is optionally cyclized via a disulfide bond between B3 and Y1; and

iii) when B6 is Phe, Y1 is Cys, and Y2 is Lys, then J is Pro, Arg, Gly, -Pro-Arg-, -Pro-Arg-Ser-, -Pro-Arg-Ser-Lys-(SEQ ID NO:249), or absent.

5. The hepcidin analogue or pharmaceutically acceptable salt or solvate thereof according to any one of claims 1-4, wherein:

(a) B1 is F, Dpa, BIP, or bhPhe; B2 is Pro, NCP, (D)Pro, or (D)NCP; B3 is Cys, a-MeCys, or homoCys; B4 is Ile; B5 is Lys or (D)Lys; B6 is Phe, substituted Phe, bhPhe, or 2Pal; and B7 is Lys, or (D)Lys; and/or

(b) B2 is Pro, or NPC, B3 is Cys, B4 is Ile, and B6 is Phe, bhPhe, or 2Pal.

6. The hepcidin analogue or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein:

(a) the peptide is according to formula IV or V:

$R^1$-Xbb1-Thr-His-B1-Pro-Cys-Ile-B5-B6-N(H)C[$CH_2$N(H)L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (IV),

or

$R^1$-Xbb1-Thr-His-B1-Pro-Cys-Ile-B5-B6-N(H)C[$CH_2CH_2CH_2CH_2$N(H)L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (V)

wherein $R^1$, $R^2$, L1, Z, J, Y1, and Y2 are as in claim 1; and

B1 is is Phe, Phe(4-F), Phe(4-CF3), Phe(2,3,5-trifluoro); B5 is (D)Lys; and B6 is Phe, bhPhe, 2Pal; or

(b) the peptide is according to formula VI or CIIb:

$R^1$-Xbb1-Thr-His-B1-Pro-Cys-Ile-(D)Lys-B6-N(H)C[$CH_2$N(H)L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (VI), or

$R^1$-Xbb1-Thr-His-B1-Pro-Cys-Ile-(D)Lys-B6-N(H)C[$CH_2CH_2CH_2CH_2$N(H)L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (VII),

wherein $R^1$, $R^2$, L1, Z, J, Y1, and Y2 are as in claim 1; and

B1 is is Phe, Phe(4-F), Phe(4-CF3), Phe(2,3,5-trifluoro); and B6 is Phe, bhPhe, or 2Pal ; or

(c) wherein the analague or pharmaceutical acceptable salt or solvate is according to claim 2, and further wherein the peptide is according to formula VIII or IX:

$R^1$-Xbb1-Thr-His-F-Pro-Cys-Ile-(D)Lys-B6-N(H)C[$CH_2CH_2CH_2CH_2N(H)$L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (VIII), or

$R^1$-Xbb1-Thr-His-Dpa-Pro-Cys-Ile-(D)Lys-B6-N(H)C[$CH_2CH_2CH_2CH_2N(H)$L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (IX),

wherein $R^1$, $R^2$, L1, Z, J, Y1, and Y2 are as in claim 1; and B6 is Phe, Phe(4-F), Phe(4-CF3), Phe(2,3,5-trifluoro), bhPhe, 2Pal; or

(d) wherein the analague or pharmaceutical acceptable salt or solvate is according to any one of claims 3 to 5(a), and further wherein the peptide is according to formula Xa, Xb, Xc, or Xd:

$R^1$-Xbb1-Thr-His-F-Pro-Cys-Ile-(D)Lys-Phe-N(H)C[$CH_2CH_2CH_2CH_2N(H)$L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (Xa),

$R^1$-Xbb1-Thr-His-Dpa-Pro-Cys-Ile-(D)Lys-Phe-N(H)C[$CH_2CH_2CH_2CH_2N(H)$L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (Xb),

$R^1$-Xbb1-Thr-His-F-Pro-Cys-Ile-(D)Lys-bhPhe-N(H)C[$CH_2CH_2CH_2CH_2N(H)$L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (Xc),

$R^1$-Xbb1-Thr-His-Dpa-Pro-Cys-Ile-(D)Lys-bhPhe-N(H)C[$CH_2CH_2CH_2CH_2N(H)$L1Z](H)-C(O)-J-Y1-Y2-$R^2$ (Xd),

wherein $R^1$, $R^2$, L1, Z, J, Y1, and Y2 are as in claim 1.

7. The hepcidin analogue or pharmaceutically acceptable salt or solvate thereof according to any one of claims 1-5, wherein:

(a) -J-Y1-Y2- is -Cys-, -Pro-Cys-, -Lys-Cys-, -(D)Lys-Cys-, -Arg-Cys-, -Dap-Cys-, -Cys-(D)Lys-, -Dap-hCys-, -Pro-Arg-Cys-, -Pro-Arg-Ser-Cys-(SEQ ID NO:253), -Pro-Arg-Ser-Lys-Cys-(SEQ ID NO:254), -His-(D)Phe-Arg-Trp-Cys-, or -Pro-Arg-Ser-Lys-Sar-Cys-(SEQ ID NO:255); or

(b) -J-Y1-Y2- is -Arg-Cys-, -(D)Lys-Cys- or -Lys-Cys- or

(c) -J-Y1-Y2- is -Cys-(D)Lys-; or

(d) -J-Y1-Y2- is -Pro-Arg-Ser-Lys-Cys-(SEQ ID NO:254).

(e) -J-Y1-Y2- is -Pro-Arg-Ser-Lys-Cys-Lys-(SEQ ID NO:255); or

(f) -J-Y1-Y2- is -Pro-Cys-; or

(g) -J-Y1-Y2- is -Cys-; or

(h) -J-Y1-Y2- is -(D)Lys-Pen-.

8. The hepcidin analogue or pharmaceutically acceptable salt or solvate thereof according to claim 1, wherein:

(a) the peptide is according to Formula XXI:

$R^1$-Xbb1-Thr-His-B1-B2-Cys-Ile-B5(L1Z)-B6-B7-J-Y1-Y2-$R^2$ (XXI)

wherein:

L1, Z, J, Y1, and Y2 are as described in claim 1;

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, $C_2$-$C_{20}$ alkenoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is Glu, substituted Glu, IsoGlu, (D)Glu, (D)isoGlu, bhGlu, or bGlu;

each of B1 and B6 is independently Phe, substituted Phe, Dpa, substituted Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;

B2 is Pro, substituted Pro, propanoicPro, butanoicPro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;

B5 is Lys or (D)Lys; and

B7 is Glu or absent; or

(b) the peptide is according to Formula XXII:

$R^1$-Xbb1-Thr-His-B1-B2-Cys-Ile-B5(L1Z)-B6-B7(L1Z)-J-Y1-Y2-$R^2$ (XXII)

wherein:

L1, Z, J, Y1, and Y2 are as described in claim;

$R^1$ is hydrogen, $C_1$-$C_6$ alkyl, $C_6$-$C_{12}$ aryl, $C_6$-$C_{12}$ aryl-$C_1$-$C_6$ alkyl, $C_1$-$C_{20}$ alkanoyl, $C_2$-$C_{20}$ alkenoyl, or $C_1$-$C_{20}$ cycloalkanoyl;

$R^2$ is $NH_2$ or OH;

Xbb1 is Glu, substituted Glu, IsoGlu, (D)Glu, (D)isoGlu, bhGlu, or bGlu;

each of B1 and B6 is independently Phe, substituted Phe, Dpa, substituted Dpa, bhPhe, a-MePhe, NMe-Phe, D-Phe, or 2Pal;

B2 is Pro, substituted Pro, propanoicPro, butanoicPro, D-Pro, bhPro, D-bhPro, NPC, or D-NPC;

B5 is Lys or (D)Lys; and

B7 is Lys or (D)Lys.

9. The hepcidin analogue or pharmaceutically acceptable salt or solvate thereof according to any one of claims 1-8, wherein:

(i) -L1Z is:

-PEG11_OMe;

-PEG12_ C18 acid;

-1PEG2_1PEG2_Ahx_Palm;

-1PEG2_Ahx_Palm;

-Ado_Palm;

-Ahx_Palm;

-Ahx_PEG20K;

-PEG12_Ahx_IsoGlu_Behenic;

-PEG12_Ahx_Palm;

-PEG12_DEKHKS_Palm;

-PEG12_IsoGlu_C18 acid;

-PEG12_Ahx_C18 acid;

-PEG12_IsoGlu_Palm;

-PEG12_KKK_Palm;

-PEG12_KKKG_Palm;

-PEG12_DEKHKS_Palm;

-PEG12_Palm;

-PEG12_PEG12_Palm;

-PEG20K;

-PEG4_Ahx_Palm;

-PEG4_Palm;

-PEG8_Ahx_Palm; or

-IsoGlu_Palm;

wherein

PEG11_OMe is –[C(O)-$CH_2$-$CH_2$–$(OCH_2CH_2)_{11}$-OMe];

1PEG2 is –C(O)-$CH_2$–$(OCH_2CH_2)_2$-NH-;

PEG4 is –C(O)-$CH_2$-$CH_2$–$(OCH_2CH_2)_4$-NH-;

PEG8 is –[C(O)-$CH_2$-$CH_2$–$(OCH_2CH_2)_8$-NH-;

1PEG8 is –[C(O)-$CH_2$–$(OCH_2CH_2)_8$-NH-;


PEG12 is –[C(O)-$CH_2$-$CH_2$–$(OCH_2CH_2)_{12}$-NH-;

Ado is –[C(O)-$(CH_2)_{11}$-NH]-

Cn acid is -C(O)$(CH_2)_{n-2}$-$CH_3$; C18 acid is -C(O)-$(CH_2)_{16}$-Me;

Palm is -C(O)-$(CH_2)_{14}$-Me;

isoGlu is isoglutamic acid;

isoGlu_Palm is  ; and

Ahx is –[C(O)-$(CH_2)_5$-NH]-; or

(ii) L1Z is:

-1PEG2_1PEG2_Dap_C18_Diacid;

-1PEG2_1PEG2_IsoGlu_C10_Diacid;

-1PEG2_1PEG2_IsoGlu_C12_Diacid;

-1PEG2_1PEG2_IsoGlu_C14_Diacid;

-1PEG2_1PEG2_IsoGlu_C16_Diacid;

-1PEG2_1PEG2_IsoGlu_C18_Diacid;

-1PEG2_1PEG2_IsoGlu_C22_Diacid;

-1PEG2_1PEG2_Ahx_C18_Diacid;

-1PEG2_1PEG2_ C18_Diacid;

-1PEG8_IsoGlu_C18_Diacid;

-IsoGlu_C18_Diacid;

-PEG12_Ahx_C18_Diacid;

-PEG12_C16_Diacid;

-PEG12_C18_Diacid;

-1PEG2_1PEG2_1PEG2_ C18_Diacid;

-1PEG2_1PEG2_1PEG2_ IsoGlu_C18_Diacid;

-PEG12_IsoGlu_C18_Diacid;

-PEG4_IsoGlu_C18_Diacid; or

-PEG4_PEG4_IsoGlu_C18_Diacid;


wherein

1PEG2, 1PEG8, PEG4, and PEG12, are as described in (i);

Cn_Diacid is -C(O)-$(CH_2)_{n-2}$-COOH; wherein n is 10, 12, 14, 16, 18, or 22.


10. The hepcidin analogue or pharmaceutically acceptable salt or solvate thereof according to any one of claims 1-9, wherein:

(a) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(1PEG2_1PEG2_IsoGlu_$C_n$_Diacid); and Lys(1PEG2_1PEG2_IsoGlu_$C_n$_Diacid) is




and n is 10, 12, 14, 16, or 18; or

(b) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(1PEG2_1PEG2_IsoGlu_$C_n$_Diacid); and (D)Lys(1PEG2_1PEG2_IsoGlu_$C_n$_Diacid) is




and n is 10, 12, 14, 16, or 18; or

(c) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(1PEG8_IsoGlu_$C_n$_Diacid); and Lys(1PEG8_IsoGlu_$C_n$_Diacid) is




and n is 10, 12, 14, 16, or 18; or

(d) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(1PEG8_IsoGlu_$C_n$_Diacid); and (D)Lys(1PEG8_IsoGlu_$C_n$_Diacid) is



and n is 10, 12, 14, 16, or 18; or


(e) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(1PEG2_1PEG2_Dap_$C_n$_Diacid); and Lys(1PEG2_1PEG2_Dap_$C_n$_Diacid) is



and

n is 10, 12, 14, 16, or 18; or


(f) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(IsoGlu_$C_n$_Diacid); and Lys(IsoGlu_$C_n$_Diacid) is



;

and n is 10, 12, 14, 16, or 18; or


(g) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(IsoGlu_$C_n$_Diacid); and (D)Lys(IsoGlu_$C_n$_Diacid) is



;

and n is 10, 12, 14, 16, or 18; or


(h) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(PEG12_IsoGlu_$C_n$_Diacid); and Lys(PEG12_IsoGlu_$C_n$_Diacid) is



;

and n is 10, 12, 14, 16, or 18; or


(i) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(PEG12_IsoGlu_$C_n$_Diacid); and (D)Lys(PEG12_IsoGlu_$C_n$_Diacid) is



;

and n is 10, 12, 14, 16, or 18; or


(j) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(PEG4_IsoGlu_$C_n$_Diacid); and Lys(PEG4_IsoGlu_$C_n$_Diacid) is



;

and n is 10, 12, 14, 16, or 18; or


(k) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(PEG4_IsoGlu_$C_n$_Diacid); and (D)Lys(PEG4_IsoGlu_$C_n$_Diacid) is



;

and n is 10, 12, 14, 16, or 18; or


(l) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(PEG4_PEG4_IsoGlu_$C_n$_Diacid); and Lys(PEG4_PEG4_IsoGlu_$C_n$_Diacid) is



; and

n is 10, 12, 14, 16, or 18; or


(m) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(PEG4_PEG4_IsoGlu_$C_n$_Diacid); and (D)Lys(PEG4_PEG4_IsoGlu_$C_n$_Diacid) is


; and

n is 10, 12, 14, 16, or 18; or

(n) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(IsoGlu_$C_n$_Diacid); and


Lys(IsoGlu_$C_n$_Diacid) is


;

and n is 10, 12, 14, 16, or 18; or

(o) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(IsoGlu_$C_n$_Diacid); and


(D)Lys(IsoGlu_$C_n$_Diacid) is


;

and n is 10, 12, 14, 16, or 18; or

(p) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(PEG12_Ahx_$C_n$_Diacid); and


Lys(PEG12_Ahx_$C_n$_Diacid) is


; and n is

10, 12, 14, 16, or 18; or

(q) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(PEG12_Ahx_$C_n$_Diacid); and

Lys(PEG12_Ahx_$C_n$_Diacid) is




;

and n is 10, 12, 14, 16, or 18; or

(r) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(PEG12_Ahx_$C_n$_Diacid); and


(D)Lys(PEG12_Ahx_$C_n$_Diacid) is



;

and n is 10, 12, 14, 16, or 18; or

(s) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is Lys(PEG12_ $C_n$_Diacid); and Lys(PEG12_ $C_n$_Diacid) is




;

and n is 10, 12, 14, 16, or 18; or

(t) Xaa1 (B5(L1Z)) or Xaa2 (B7(L1Z)) is (D)Lys(PEG12_ $C_n$_Diacid); and

(D)Lys(PEG12_ $C_n$_Diacid) is




;


and n is 10, 12, 14, 16, or 18.

11. A hepcidin analogue, or a pharmaceutically acceptable salt or solvate thereof, comprising or consisting of a peptide according to claim 1, wherein the peptide is:


Compound ID# 12




Compound ID# 19




Compound ID# 107




Compound ID# 113




Compound ID# 256




Compound ID# 257




Compound ID# 280



Compound ID# 281




Compound ID# 255



or

Compound ID 280



.

12. A hepcidin analogue, or a pharmaceutically acceptable salt or solvate thereof, comprising or consisting of a peptide according to claim 1, wherein the peptide is any one of the following:

| Compound # / SEQ ID No. | Peptide |
|---|---|
| Ref. Compd. 2 (Ref-1) | Isovaleric acid-DTHFPCIKF-Lys[2Peg11'-Palm]-PRSKGCK-$NH_2$ |
| 1 | Isovaleric Acid-E-T-H-F-P-[Cys]-I-[(D)Lys]-F-[Lys(2Peg11'_Palm)]-K-[Cys]-$NH_2$; |
| 2 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[Dpa]-[Lys(2Peg11'_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 3 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 4 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Palm)]-[Cys]-[(D)Lys]-$NH_2$; |
| 5 | Isovaleric Acid-E-T-H-[Dpa]-[Npc]-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 6 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 7 | Isovaleric Acid-[bhGlu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 8 | Isovaleric Acid-[bGlu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 9 | Isovaleric Acid-[(OMe)Asp]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 10 | Isovaleric Acid-[Gla]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 11 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-R-[Cys]-$NH_2$; |
| 12 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 13 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 14 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-[bhPhe]-R-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 15 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-R-[Cys]-$NH_2$; |
| 16 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-R-[Cys]-$NH_2$; |
| 17 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Palm)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 18 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys(2Peg11'_OMe)]-[bhPhe]-[Lys(Ahx_Palm)]-R-[Cys]-$NH_2$; |
| 19 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I- [(D)Lys(2Peg11'_OMe)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys(2Peg11'_OMe)]-[Cys]-$NH_2$; |
| 20 | Isovaleric Acid-[Glp]-T-H-F-P-[Cys]-I-Z_minus-F-E-P-R-S-K-G-[Cys]-K-$NH_2$; |
| 21 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Palm)]-[2Pal]-[Cys]-$NH_2$; |
| 22 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Palm)]-[2Pal]-R-[Cys]-$NH_2$; |
| 23 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-[2Pal]-R-[Cys]-$NH_2$; |
| 24 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-[2Pal]-R-[Cys]-$NH_2$; |
| 25 | Isovaleric Acid-E-T-H-F-P-[Cys]-I-K-F-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-P-R-S-K-[Sarc]-[Cys]-K-$NH_2$; |
| 26 | Isovaleric Acid-E-T-H-F-P-[Cys]-I-K-F-[Lys(1Peg2_1Peg2_Ahx_C18_Diacid)]-P-R-S-K-[Sarc]-[Cys]-K-$NH_2$; |
| 27 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 28 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[a-MePhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 29 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 30 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Ahx_IsoGlu_C18Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 31 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Ahx_IsoGlu_Behenic_acid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 32 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 33 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 34 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 35 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ado_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 36 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ado_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 37 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ado_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 38 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_2Peg11'_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 39 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg4_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 40 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg4_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 41 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 42 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-K-R-[Cys]-$NH_2$; |
| 43 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-K-R-[Cys]-$NH_2$; |
| 44 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx)]-R-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 45 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-K-[bhPhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 46 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[Lys(2Peg20K)]-R-[Cys]-$NH_2$; |
| 47 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-[Lys(2Peg20K)]-R-[Cys]-$NH_2$; |
| 48 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx_PEG20K)]-R-[Cys]-$NH_2$; |
| 49 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg20K)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 50 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg20K)]-[bhPhe]-[Lys(2Peg11'_Palm)]-R-[Cys]-$NH_2$; |
| 51 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_PEG20K)]-[bhPhe]-R-[Cys]-$NH_2$; |
| 52 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys([Lys(2_2Peg11'_Palm)])]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 53 | Isovaleric Acid-E-T-H-[(4F)Phe]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 54 | Isovaleric Acid-E-T-H-[(4CF3)Phe]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 55 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[(4F)Phe]-[(D)Lys]-[Cys]-$NH_2$; |
| 56 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[(4CF3)Phe]-[(D)Lys]-[Cys]-$NH_2$; |
| 57 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_KKK_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 58 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_DEKHKS_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 59 | Isovaleric Acid-E-T-H-[(2,3,5-trifluoro)Phe]-P-[Cys]-I-[Lys(2Peg11'_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 60 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1Peg2_Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 61 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg8_Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 62 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 63 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg8_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 64 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 65 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_[Lys(DEKHKS_Palm)])]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 66 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_KKKG_Palm)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 67 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[a-MePhe]-[Lys(2Peg11'_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 68 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(IsoGlu_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 69 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg4_Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 70 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 71 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Lys[2Peg11'_Palm]2)]-[(D)Lys]-[Cys]-$NH_2$; |
| 72 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_AlbuTag)]-[(D)Lys]-[Cys]-$NH_2$; |
| 73 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_C18_Diacid)]-[(D)Lys]-[Cys]-$NH_2$; |
| 74 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(2Peg11'_Palm)]-[(D)Lys]-[Pen]-$NH_2$; |
| 75 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Ala]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 76 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Ala]-[Cys]-$NH_2$; |
| 77 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Pen]-$NH_2$; |
| 78 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 79 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[Cys]-$NH_2$; |
| 80 | Isovaleric Acid-E-T-H-[(Me)Phe]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 81 | Isovaleric Acid-E-T-H-[Dpa]-P-[(Me)Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 82 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-[(Me)Ile]-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 83 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(Me)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 84 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[(Me)Phe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 85 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[(Me)Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 86 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(Me)Lys]-[Cys]-$NH_2$; |
| 87 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[(Me)Cys]-$NH_2$; |
| 88 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-L-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 89 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Leu]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 90 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Leu]-[Cys]-$NH_2$; |
| 91 | Isovaleric Acid-[(OMe)Glu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 92 | Isovaleric Acid-[(OMe)Glu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[Lys(Ac)]-[Cys]-$NH_2$; |
| 93 | Isovaleric Acid-E-T-H-[Dpa]-P-[(D)Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 94 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[(D)Cys]-$NH_2$; |
| 95 | Isovaleric Acid-E-T-H-[Dpa]-P-[(D)Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[(D)Cys]-$NH_2$; |
| 96 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys_IVA)]-[Cys]-$NH_2$; |
| 97 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys_IVA)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 98 | [Diacid_C18_isoGlu_PEG2_PEG2]-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 99 | [C18_diacid_Ahx_PEG2_PEG2]-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 100 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-H-[(D)Phe]-R-W-[Cys]-$NH_2$; |
| 101 | Isovaleric Acid-E-T-H-F-P-[Cys]-I-Z_minus-F-E-P-R-S-K-G-[Cys]-K-$NH_2$; |
| 102 | Isovaleric Acid-[(Me)Glu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-$NH_2$; |
| 103 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ahx_Palm)]-[bhPhe]-L-[(D)Lys]-[Cys]-$NH_2$; |
| 104 | Isovaleric Acid-[(OMe)Glu]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[Cys]-$NH_2$; |
| 105 | Isovaleric Acid-[(OMe)Glu]-T-H-[Dpa]-P-[Cys]-I-[bhPhe]-[Lys(Ahx_Palm)]-[Lys(Ac)]-[Cys]-$NH_2$; |
| 106 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys_IVA)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys_IVA)]-[Cys]-$NH_2$; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 107 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 108 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C14_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 109 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C16_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 110 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 111 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C20_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 112 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_IsoGlu_C18)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 113 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg11'_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 114 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 115 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg4_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 116 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 117 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(2Peg8_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 118 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 119 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1Peg2_1Peg2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-$NH_2$; |
| 120 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-NH2; |
| 121 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 122 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-E-NH2; |
| 123 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-[(D)Glu]-NH2; |
| 124 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-D-NH2; |
| 125 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-[(D)Asp]-NH2; |
| 126 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-Gla-NH2; |
| 127 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-[Tet1]-NH2; |
| 128 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys(Ac)]-[Cys]-[Tet2]-NH2; |
| 129 | Isovaleric Acid-E-T-H-[Dpa]-[bhPro]-[Lys(Ahx_Palm)]-[bhPhe]-NH2; |
| 130 | $Me_2$-$(CH_2)_2$-NH-C(O)-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-NH2; |
| 131 | Isovaleric Acid-[N-(CH2CH2CH2CO2H)Gly]-T-H-[Dpa]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-NH2; |
| 132 | Isovaleric Acid-E-T-H-[N-(CH2CH2C(Ph)2)Gly]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-NH2; |
| 133 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-[N-(isopentyl)Gly]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Cys]-NH2; |
| 134 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-(CH2CH2Ph)Gly]-[(D)Lys]-[Cys]-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 135 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[N-((CH2)5NH2)Gly]-[Cys]-NH2; |
| | |
| 201 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx)]-[bhPhe]-R-C-NH2; |
| 202 | Isovaleric Acid-E-T-[His_1Me]-[Dpa]-P-C-I-[Lys(PEG12_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 203 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-A-[(D)Lys]-C-NH2; |
| 204 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG8_Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 205 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 206 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 207 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-[Sarc]-C-NH2; |
| 208 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-L-C-NH2; |
| 209 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-F-C-NH2; |
| 210 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-G-C-NH2; |
| 211 | Isovaleric Acid-E-T-H-F-P-C-I-K-F-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-P-R-S-K-G-[Pen]-K-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 212 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-T |
| 213 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-E |
| 214 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-[Lys(Ac)]-G-C-T |
| 215 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-[Lys(Ac)]-G-C-E |
| 218 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-C-NH2 |
| 220 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 221 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 222 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_C18_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 223 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(Ahx_Palm)]-F-E-P-R-S-K-G-C-K-NH2; |
| 224 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 225 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-R-S-K-G-C-NH2; |
| 226 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-R-S-G-C-NH2; |
| 227 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-[(D)Arg]-S-K-G-C-K-NH2; |
| 228 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-[Lys(Ac)]-S-K-G-C-K-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 229 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-[Lys(Ac)]-S-K-G-[Pen]-K-NH2; |
| 230 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(IsoGlu_Palm)]-F-E-P-[Lys(Ac)]-S-G-C-NH2; |
| 231 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(IsoGlu_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 232 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C16_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 233 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C14_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 234 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C12_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 235 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C10_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 236 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 237 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG4_PEG4_IsoGlu_C18_Diacid)]-[bhF]-[(D)Lys]-C-NH2; |
| 238 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG8_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 239 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG4_IsoGlu_C18_Diacid)]-[bhF]-[(D)Lys]-C-NH2; |
| 240 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(IsoGlu_C18_Diacid)]-[bhF]-[(D)Lys]-C-NH2; |
| 241 | Octanoic_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 242 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C16_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 243 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C14_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 244 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C12_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 245 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C10_Diacid)]-F-E-P-R-S-K-G-C-K-NH2; |
| 246 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C16_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 247 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C14_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 248 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C12_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 249 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C10_Diacid)]-F-E-P-R-S-K-G-C-NH2; |
| 254 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_1PEG2_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 255 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 256 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG7_OMe)]-C-NH2; |
| 257 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG3_OMe)]-C-NH2; |
| 259 | Butyric_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 260 | Cyclohexanecarboxylic_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 261 | Heptanoic_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 263 | Hexanoic_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 264 | Valeric_Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 265 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C16_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 266 | Isovaleric Acid-bE-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 267 | Isovaleric Acid-bhE-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 268 | Isovaleric Acid-Gla-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 269 | Isovaleric Acid-meE-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 271 | Isovaleric Acid-E-T-H-[Phe(2,3-diF]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 272 | Isovaleric Acid-E-T-H-[Dpa]-[Npc]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 273 | Isovaleric Acid-E-T-H-[Dpa]-[bhPhe]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 274 | Isovaleric Acid-E-T-H-[Dpa]-[PropanoicP]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 275 | Isovaleric Acid-E-T-H-[Dpa]-[ButanoicP]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 276 | Isovaleric Acid-E-T-H-[Dpa]-[Pro(4,4-diF)]-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 277 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 278 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 279 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 280 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 281 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 282 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm-(D)Lys_Acrylamide)]-C-NH2; |
| 283 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys(Acrylamide)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2; |
| 284 | Acrylic_Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)-[(D)Lys]-C-NH2; |
| 285 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[Lys(PEG11_OMe)]-C-NH2; |
| 286 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[Lys(PEG11_OMe)]-C-NH2; |
| 287 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG11_OMe-[bhPhe]-[Lys(Ahx_Palm)]-[Lys(PEG11_OMe)]-C-NH2; |
| 288 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys(PEG11_OMe-[bhPhe]-[Lys(IsoGlu_Palm)]-[(D)Lys(PEG11_OMe)]-C-NH2; |
| 289 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_OMe-[bhPhe]-[(D)Lys]-C-NH2; |
| 290 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(Ac-C-NH2; |
| 291 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_IsoGlu_Palm)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2; |
| 292 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2; |
| 293 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 294 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_Palm)]-[bhPhe]-[Lys(PEG30K)]-R-C-NH2; |
| 295 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_Palm)]-[bhPhe]-[Lys(PEG40KB)]-R-C-NH2; |
| 296 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG40KB)]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2; |
| 297 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG40KB-C-NH2; |
| 298 | Isovaleric Acid-[(D)Glu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 299 | Isovaleric Acid-[IsoGlu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 300 | Isovaleric Acid-[(D)IsoGlu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 301 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_C18_Diacid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 302 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_Ahx_C18_Diacid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 303 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_C18 acid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 304 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_Ahx_C18 acid)]-F-E-P-R-S-K-G-[Pen]-K-NH2; |
| 305 | Isovaleric Acid-E-T-H-F-P-C-I-[Lys(PEG12_C18_Diacid)]-F-E-P-R-S-K-G-Abu-K-NH2; |
| 306 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18 acid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 307 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_Ahx_C18 acid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 308 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-Abu-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 309 | Isovaleric_Acid-IsoGlu-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 310 | Isovaleric Acid-[(D)Glu]-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 311 | Isovaleric_Acid-dIsoGlu-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 312 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys(PEG20K)]-C-NH2; |
| 313 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys(PEG20K)]-R-C-NH2; |
| 314 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_Palm)]-[bhPhe]-[(D)Lys(PEG20K-C-NH2; |
| 315 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_C18_Diacid)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 316 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 317 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(IsoGlu_Palm)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 318 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 319 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-[Pen]-NH2; |
| 320 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_C18)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 321 | Isovaleric Acid-[Glu_OMe]-T-His_1Me-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 322 | Isovaleric Acid-[MeGlu]-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 323 | IsovalerAldehyde-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 324 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-C-I-[Lys(Ahx_Palm)]-[bhPhe]-[(D)Lys]-C-NH2; |
| 325 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys(Gal)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2; |
| 326 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Gal)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2; |
| 327 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys(Gal)]-C-NH2; |
| 328 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys(Gal)-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2; |
| 329 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[Lys(Gal)]-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2; |
| 330 | Isovaleric Acid-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]- [(D)Lys(Gal)]-C-NH2; |
| 331 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[meLys]-[bhPhe]-[Lys(Ahx_Palm)]-[meLys]-[Cys]-NH2; |
| 332 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-[Cys]-I-[meK]-[bhPhe]-[Lys(Ahx_Palm)]-[meLys]-[Cys]-NH2; |
| 333 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[(D)Lys]-[Cys]-NH2; |
| 334 | Isovaleric Acid-[Glu_OMe]-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[(D)Lys]-[Cys]-NH2; |
| 335 | [Betaine]-E-T-H-[Dpa]-P-[Cys]-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-NH2; |
| 336 | Isovaleric Acid-E-T-H-[Dpa]-P-[Cys]-I-[Lys(Betaine)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-[Cys]-NH2; |
| | |
| REF1 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| REF2 | [Isovaleric Acid]-E-T-[2Pal]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 601 | [Isovaleric Acid]-E-T-[3Quin]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 602 | [Isovaleric Acid]-E-T-[Dab]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 603 | [Isovaleric Acid]-E-T-[Dap]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 604 | [Isovaleric Acid]-E-T-[Orn]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 605 | [Isovaleric Acid]-E-S-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 606 | [Isovaleric Acid]-E-[Dap]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 607 | [Isovaleric Acid]-E-[(D)Asp]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 608 | [Isovaleric Acid]-E-S-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2 |
| 609 | [Isovaleric Acid]-E-[(D)Ser]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2 |
| 610 | [Isovaleric Acid]-E-[Dab]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2 |
| 611 | [Isovaleric Acid]-E-S-H-[Dpa]-P-C-I-[(D)Lys]-[aMePhe]-[Lys(PEG12_Palm)]-[(D)Lys]-C-NH2 |
| 612 | [Isovaleric Acid]-E-A-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 613 | [Isovaleric Acid]-E-T-A-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 614 | [Isovaleric Acid]-E-T-A-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 615 | [Isovaleric Acid]-E-[N-MeThr]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 616 | [Isovaleric Acid]-E-T-[N-MeHis]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 617 | [Isovaleric Acid]-E-L-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 618 | [Isovaleric Acid]-E-T-L-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 619 | [Isovaleric Acid]-E-[Hyp]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 620 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 621 | [Isovaleric Acid]-E-T-[2Pal]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_Palm)]-R-C-NH2 |
| 622 | Isovaleric Acid-[Tet1]-T-[His_1Me]-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys]-[Cys]-NH2 |
| 623 | Isovaleric Acid-[Tet1]-T-[His_1Me]-[Dpa]-P-[Cys]-I-[Lys(Ac)]-[bhPhe]-[(D)Lys]-[Cys]-E-NH2 |
| | |
| 401 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Tyr]-NH2 |
| 402 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Ser]-NH2 |
| 403 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Gln]-NH2 |
| 404 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[1Nal]-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 405 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Leu]-NH2 |
| 406 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-Me(D)Phe]-NH2 |
| 407 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MePhe]-NH2 |
| 408 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Cyclohexanoic_Acid)]-C-NH2 |
| 409 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Glutaric Acid)]-C-NH2 |
| 410 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Imidazol_AceticAcid)]-C-NH2 |
| 411 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Butanoic_Acid_3OH)]-C-NH2 |
| 412 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(DIP_CH2CO2H)]-C-NH2 |
| 413 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Phenylacetic_Acid_4F)]-C-NH2 |
| 414 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(Ahx)]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 415 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Dap(IVA)]-C-NH2 |
| 416 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid_Me)]-[bhPhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 417 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 418 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-NMe_Ile-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 419 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 420 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-NMe_Ile-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 421 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 422 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 423 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-NMe_Ile-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[N-Me(D)Lys(PEG11_OMe)]-C-NH2 |
| 424 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MeTyr]-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 425 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MeSer]-NH2 |
| 426 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MeGln]-NH2 |
| 427 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[2Nal]-NH2 |
| 428 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-[N-MeLeu]-NH2 |
| 429 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys_PEG15_OMe]-C-NH2 |
| 430 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG23_OMe)]-C-NH2 |
| 431 | [Isovaleric Acid]-E-T-H-[Dpa]-P-[N-MeCys]-NMe_Ile-[N-MeLys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[N-MePhe]-[N-Me(D)Lys(PEG11_OMe)]-[N-MeCys]-NH2 |
| 432 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[Dpa]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 433 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[aMePhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 434 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-[bhPro]-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 435 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-[Npc]-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 436 | [Isovaleric Acid]-E-T-H-[Dpa]-P-[N-MeCys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-[N-MeCys]-NH2 |
| 437 | [Isovaleric Acid]-E-T-H-[Dpa]-P-[aMeCys]-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-[aMeCys]-NH2 |
| 438 | [Isovaleric Acid]-E-T-[Trp(5-OH)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 439 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 440 | [Isovaleric Acid]-E-T-[Phe(4-CF3)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 441 | [Isovaleric Acid]-E-T-[Trp(6-OMe)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 442 | [Isovaleric Acid]-E-T-[Trp(5-OH)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 443 | [Isovaleric Acid]-E-T-[His(1-Me)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 444 | [Isovaleric Acid]-E-T-[Phe(4-CF3)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 445 | [Isovaleric Acid]-E-T-[Trp(6-OMe)]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 446 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Tle]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 447 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Tle]-C-NH2 |
| 448 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[N-MeIle]-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[N-MeLys]-C-NH2 |
| 449 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[N-MeIle]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[N-MePhe]-[(D)Lys]-C-NH2 |
| 450 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[N-MeLys]-C-NH2 |
| 451 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 452 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[Dpa]-[(D)Lys]-C-NH2 |
| 453 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[Dpa]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 454 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-[Npc]-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 455 | [Isovaleric Acid]-E-T-[3Pal]-[Dpa]-[Npc]-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 456 | [4-Fluorophenylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-OH |
| 457 | [Isovaleric Acid]-E-T-[2Quin]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG12_OMe)]-C-NH2 |
| 458 | [4-Fluorophenylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG12_OMe)]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 459 | [Cyclopentylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 460 | [Isovaleric Acid]-E-T-[Bip]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG12_OMe)]-C-NH2 |
| 461 | [Cyclopentylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG12_OMe)]-C-NH2 |
| 462 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 463 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG36_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 464 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG36_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 465 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG24_PEG24_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 466 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG24_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 467 | [Isovaleric Acid]-E-T-Y-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 468 | [Isovaleric Acid]-E-T-W-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 469 | [Isovaleric Acid]-E-T-W-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 470 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx_Palm)]-C-NH2 |
| 471 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(PEG12_Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 472 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(PEG12_PEG12_Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 473 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(PEG12_Ahx_Palm)]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 474 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-[(D)Arg]-NH2 |
| 475 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 476 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ac)]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 477 | [Isovaleric Acid]-E-T-Y-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 478 | [Isovaleric Acid]-E-T-H-F-P-C-I-[Lys(Ac)]-F-[(D)Lys]-C-NH2 |
| 479 | [Isovaleric Acid]-E-T-[3Quin]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 480 | [Isovaleric Acid]-E-T-[Bip]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 481 | [4-Fluorophenylacetic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 482 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[Lys(Me3)]-C-NH2 |
| 483 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG8_OMe)]-C-NH2 |
| 484 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG8_OMe)]-C-NH2 |
| 485 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 486 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_DMG_N_2am_C18_Diacid)]-[bhPhe]-[(D)Lys(Betaine)]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 487 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_DMG_N_2am_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 488 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_ParaBenzoate_Hydroxyl_10C_Acid)]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_ParaBenzoate_Hydroxyl_10C_Acid)]-[(D)Lys]-C-NH2 |
| 489 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_ParaBenzoate_Hydroxyl_10C_Acid)]-[bhPhe]-[(D)Lys]-[(D)Lys]-C-NH2 |
| 490 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_ParaBenzoate_Hydroxyl_10C_Acid)]-[(D)Lys]-C-NH2 |
| 491 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_MetaBenzoate_Hydroxyl_9C_Acid)]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_MetaBenzoate_Hydroxyl_9C_Acid)]-[(D)Lys]-C-NH2 |
| 492 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_MetaBenzoate_Hydroxyl_9C_Acid)]-[bhPhe]-[(D)Lys]-[(D)Lys]-C-NH2 |
| 493 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_MetaBenzoate_Hydroxyl_9C_Acid)]-[(D)Lys]-C-NH2 |
| 494 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-[(D)Cys]-I-[(D)Lys]-[bhPhe]-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[(D)Lys]-C-NH2 |
| 495 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-[(D)Cys]-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 498 | [Isovaleric Acid]-[Glu(OMe)]-T-W-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 500 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-[(D)Arg]-NH2 |
| 501 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 502 | [Isovaleric Acid]-[Dap]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Arg]-C-NH2 |
| 503 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Phe(4-COOH)]-[(D)Lys]-C-NH2 |
| 504 | [Isovaleric Acid]-[IsoGlu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 505 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe(4-Me)]-[(D)Lys]-C-NH2 |
| 506 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Aic]-[(D)Lys]-C-NH2 |
| 507 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Achc]-[(D)Lys]-C-NH2 |
| 508 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Hph]-[(D)Lys]-C-NH2 |
| 509 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[hLeu]-[(D)Lys]-C-NH2 |
| 510 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-F-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 511 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[Cha]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 512 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[Achc]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 513 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[aMeLeu]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 514 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[Tle]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 515 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[hLeu]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 516 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_PEG12_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 517 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 518 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(Ac)]-C-NH2 |
| 519 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(PEG12_PEG12_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 520 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(PEG12_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 521 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(Ac)]-C-NH2 |
| 522 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[Igl]-[(D)Lys]-C-NH2 |
| 523 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 524 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 525 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(DMG_N_2ae_Palm)]-[(D)Lys]-C-NH2 |
| 526 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(DMG_N_2ae_Palm)]-[(D)Lys]-C-NH2 |
| 527 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_DMG_N_2ae_Palm)]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 528 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_DMG_N_2ae_Palm)]-[(D)Lys]-C-NH2 |
| 529 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG12_DMG_N_2ae_Palm)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 530 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(PEG12_DMG_N_2ae_Palm)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 531 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(Ahx_DMG_N_2ae_Palm)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 532 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(Ahx_DMG_N_2ae_Palm)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 533 | [Isovaleric Acid]-[IsoGlu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 534 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-[(D)Arg]-NH2 |
| 535 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Arg]-C-NH2 |
| 536 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-[(D)Arg]-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 537 | [Isovaleric Acid]-[(D)Arg]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 538 | [Isovaleric Acid]-[Dap]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Dap_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 539 | [Isovaleric Acid]-[(D)IsoGlu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 540 | [Isovaleric Acid]-[(D)Glu]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys(PEG11_OMe)]-C-NH2 |
| 541 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[N-MeLys(Ahx_Palm)]-[(D)Lys(Carnitine)]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 542 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[N-MeLys(Ahx_Palm)]-[bhPhe]-[(D)Lys(Carnitine)]-C-NH2 |
| 543 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys(Carnitine)]-C-NH2 |
| 544 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 545 | [Isovaleric Acid]-[Glu(OMe)]-T-H-[Dpa]-P-C-I-[Lys(PEG2_1PEG2_DMG_N_2ae_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 546 | [Isovaleric Acid]-E-[Dab]-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 547 | [Isovaleric Acid]-E-[Dap]-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 548 | [Isovaleric Acid]-E-[Dab]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 549 | [Isovaleric Acid]-E-[Dap]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 550 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[Amb]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 551 | [Isovaleric Acid]-E-[Lys(Acrylamide)]-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 552 | [Isovaleric Acid]-E-T-[Lys(Acrylamide)]-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 553 | [Isovaleric Acid]-E-T-H-[Lys(Acrylamide)]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 554 | [Isovaleric Acid]-E-T-H-[Dpa]-[Lys(Acrylamide)]-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 555 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[(D)Lys(Acrylamide)]-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 556 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[Lys(Acrylamide)]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 557 | [Isovaleric Acid]-[Dap]-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 558 | [Isovaleric Acid]-E-T-H-[Dpa]-S-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 559 | [Octanoic Acid]-E-T-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 560 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[(D)Lys(Gal)]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 561 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[Lys(Gal)]-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 562 | [Cyclohexanoic Acid]-E-T-H-[Dpa]-P-C-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 563 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-[bhPhe]-[Lys(1PEG2_1PEG2_IsoGlu_C18_Diacid)]-C-OH |
| 564 | [Isovaleric Acid]-E-T-[N-(Imidazolethyl)Gly]-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 565 | [Isovaleric Acid]-E-[N-(hydroxyethyl)Gly]-H-[Dpa]-P-C-I-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-C-NH2 |
| 566 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[Amb]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 567 | [Isovaleric Acid]-E-T-H-[Dpa]-[N-MeAla]-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 568 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-L-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 569 | [Isovaleric Acid]-E-T-H-[Dpa]-L-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |

| Compound # / SEQ ID No. | Peptide |
|---|---|
| 570 | [Isovaleric Acid]-E-T-H-L-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 571 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 572 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-[(D)Lys]-A-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 573 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-A-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 574 | [Isovaleric Acid]-E-T-H-[Dpa]-A-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 575 | [Isovaleric Acid]-E-T-H-A-P-C-I-[(D)Lys]-[bhPhe]-[Lys(Ahx_Palm)]-[(D)Lys]-C-NH2 |
| 576 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-I-K-[bhPhe]-R-C-NH2 |
| 577 | [Isovaleric Acid]-E-T-H-[Dpa]-P-C-C-[Lys(1PEG2_1PEG2_Ahx_C18_Diacid)]-[bhPhe]-[(D)Lys]-NH2 |

13. A pharmaceutical composition comprising the hepcidin analogue or pharmaceutically acceptable salt or solvate thereof or peptide of any one of claims 1-12, and a pharmaceutically acceptable carrier, excipient or vehicle.

14. A method of binding a ferroportin or inducing ferroportin internalization and degradation, comprising contacting the ferroportin with at least one hepcidin analogue or pharmaceutically acceptable salt or solvate thereof or peptide of any one of claims 1-12.

15. Use of the hepcidin analog or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-12 or the pharmaceutical composition of claim 3 in the manufacture of a medicament for

(a) treating a disease of iron metabolism; or

(b) treating a disease or disorder associated with dysregulated hepcidin signaling, optionally wherein

the disease or disorder is a disease of iron metabolism such as an iron overload disease, hemochromatosis, a thalassemia, or a polycythemia vera.